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                                                   INTRODUCTION 
 
1. TABLETS 1, 2: 
Tablets fall in the category of solid dosage forms each containing a single dose of one or 
more active ingredients and usually obtained by compressing uniform volume of 
particles, some are prepared by molding. Most tablets are intended for oral route. The rest 
are through sublingual, buccal or vaginal. 
Advantages of tablets:  
• Packaging in blister packs can also enhance the stability of tablets. 
• Compared to liquid dosage forms chemically and physically stable. 
• Low manufacturing cost. 
• They provide a content variability. 
• Easy to package and ship. 
• Simple to identify. 
• Manufacturing process and techniques can provide tablets special properties say 
enteric coatings. 
Disadvantages of tablets: 
• Some drug resists compression in to tablet. 
• Difficulty in swallowing in some patients; pediatrics and geriatrics. 
• Poor bioavailability of poorly soluble drugs or poorly absorbable drugs. 
• Some drugs may cause local irritation effect harm GI mucosa. 
• In emergency cases, intravenous or intramuscular injections are more effective. 
. 
The objective of the design and manufacture of the compressed tablet is to deliver 
orally, the correct amount of the drug in the proper form, at or over the proper time 
and in the desired location, and to have its chemical ingredients projected to the point. 
In tablets with smaller dosages a good weight variation does not ensure good content 
uniformity, but a large weight variation precludes a good content uniformity. 
To assure uniform potency for tablets of low dose drugs, a content uniformity tests 
applied. In this test 30 tablets are randomly selected for the sample and at least 10 of 
                                                                                          INTRODUCTION 
 
Dept of Pharmaceutics, K.M College of Pharmacy, Madurai. Page 2 
 
them are assayed individually. Nine of the 10 tablets must contain not less than 85% 
or more than 115% of the labeled drug content. The tenth tablet may not contain less 
than 75% or more than 125% of the label content. If these conditions are not met, the 
tablets remaining from the 30 must be assayed individually and one may fall out side 
85% to 115% 
 
2. What is Bi-layer Tablet? 
A tablet with two mutually exclusive layers, represented by two clearly different colors, 
provided manufacturers with a way to produce a product that looked more interesting 
than a standard white pill. 
 
Bilayer Tablets – Why special technology is required? 3 
 For a variety of reasons: patent extension, therapeutic, marketing to name a few. To 
reduce capital investment, quite often existing but modified tablet presses are used to 
develop and produce such tablets. This explains why the development and production of 
quality bi-layer tablets needs to be carried out on purpose-built tablet presses to overcome 
common bi-layer problems, such as layer--separation, insufficient hardness, inaccurate 
individual layer weight control, cross-contamination between the layers, reduced yield, 
etc. Using a modified tablet press may therefore not be your best approach to producing a 
quality bi-layer tablet under GMP-conditions. Especially when in addition high 
production output is required. 
To produce a quality bi-layer tablet, in a validated and GMP-way, it is important that the 
selected press is capable of: 
• Preventing capping and separation of the two individual layers that constitute the   
          Bi-layer tablet 
• Providing sufficient tablet hardness 
• Preventing cross-contamination between the two layers 
• Producing a clear visual separation between the two layers 
• High yield 
• Accurate and individual weight control of the two layers. 
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Reasons for the use of bilayered tablet design 4: 
• Bilayered tablets are preferred when the release profiles of the drugs are 
different from one another i.e.. in the present case Hydrochlorothiazide has to 
be released immediately and Metoprolol succinate has to be released 
sustainably.  
• These provide a unique presentation and identification for the product in the 
market for that manufacturer. 
• For stagged drug release IR and SR in the same tablet. 
• For chronic condition requiring repeated dosing. 
• To co-administered two different drugs in the same dosage forms. 
• To minimize the physical and chemical incompatibilities.  
        
3. According to method of manufacturing: 
a) Compressed tablet: 
         It is obtained by compressing uniform volume of particles using “Tablet 
compression machine”. It is used for large scale production. 
b) Molded tablet: 
Molding means shaping and hardening of semi solid mixture of drug and excipients. 
It is obtained using “Tablet mold”. It is restricted for small-dose tablet and small 
scale production. 
 
4. TABLET EXCIPIENTS: 
 The tablet is composed of the drug together with various excipients. These are 
biologically inert ingredients which either enhance the therapeutic effect or 
necessary to conduct the tablet. 
a) Fillers: or diluents are a bulking agent, providing a quantity of material 
which can accurately be formed in to a tablet. 
Examples are lactose or sorbitol.   
b) Binders: These are holding the ingredients together so that they form a 
tablet. 
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Examples are Methyl cellulose or gelatin. 
c) Lubricants: These are added to reduce the friction between the tablet   
 and the punches and dies so that the tablet compression and ejection   
       processes are smooth. 
     Examples are magnesium stearate or polyethylene glycol.  
d) Disintegrants: These are used to promote wetting and swelling of the 
tablet so that it breaks up in the gastro intestinal tract; this is necessary to 
ensure dissolution of the API. 
Examples are starch or cellulose 
e) Super disintegrants: These are sometimes used to greatly speed up the 
disintegration of the tablet. 
Additional ingredients may also be added such as colorants, flavoring 
agents and coating agents. 
 
 
5.  ORAL DRUG DELIVERY 2: 
Most conventional oral drug products, such as tablets and capsules, are formulated to 
release the active drug immediately after oral administration, to obtain rapid and 
complete systemic drug absorption. Such immediate release products result in relatively 
rapid drug absorption and onset of accompanying pharmacodynamic effects. However, 
after absorption of the dosage form is complete, plasma drug concentration decline 
according to drug’s pharmacokinetic profile. Eventually, plasma drug concentration fall 
below the minimum effective plasma concentration (MEC), resulting in loss of 
therapeutic activity. Before this point is reached, another dose is usually given if a 
sustained therapeutic effect is desired. An alternative to administering another dose is to 
use a dosage form that will provide sustained drug release, and therefore maintain plasma 
drug concentrations, beyond what is typically seen using immediate- release dosage 
forms. 
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6. MODIFIED DRUG DELIVERY: 
The term modified-release drug product is used to describe products that alter the timing 
and/or the rate of release of the drug substance. A modified-release dosage form is 
defined as one for which the drug-release characteristics of time course and/or location 
are chosen to accomplish therapeutic or convenience objectives not offered by 
conventional dosage forms such as solutions, ointments, or promptly dissolving dosage 
forms as presently recognized. Several types of modified-release drug products are 
recognized. 
 
6.1 Modified release delivery systems may be divided conveniently in to four 
categories: 
 
A. Delayed release 
B. Controlled release 
i. Sustained release 
ii. Extended release 
C. Site specific targeting 
D. Receptor targeting 
 
 A. Delayed Release: 
        These systems are those that use repetitive, intermittent dosing of a drug from 
one or more immediate release units incorporated in to a single dosage form.  
Examples of delayed release systems included repeat action tablets, capsules and 
enteric-coated tablets where timed release is achieved by barrier coating. 
 B. Controlled release systems:  
            These systems include any drug delivery systems that achieves slow release of 
drug over an extended period of time and also can provide some control, where this be of 
a temporal or spatial nature, or both, of drug release in the body, or in other words, the 
system is successful at maintaining constant drug levels in the target tissue or cells. 
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i) Sustained release: 
These systems include any drug delivery system that achieves slow release 
of drug over an extended period of time. 
ii) Extended release: 
Pharmaceutical dosage forms that release the drug slower than normal 
manner and necessarily reduce the dosage frequency by two folds.  
C. Site specific targeting: 
           These systems refer to targeting of a drug directly to a certain biological location. 
In this case the target is adjacent to the effected organ or tissue. 
 
 D. Receptor targeting:  
    These systems refer to targeting of a drug directly to a certain biological location.  
In this case the target is the particular receptor for a drug with in organ or tissue. 
      Site specific targeting and receptor targeting systems satisfy the spatial aspect of drug  
      delivery and are also considered to be controlled drug delivery systems. 
 
7. EXTENDED RELEASE CONCEPT 7: 
          Over the past 30 years as the expenses and complications involved in marketing 
new drug entities have increased. With concomitant recognition if the therapeutic 
advantages of extended drug delivery, greater attention has been focused on development 
of extended or controlled release drug delivery systems. The attractiveness of these 
dosage forms is due to awareness to toxicity and other properties of drugs when 
administered or applied by conventional method in the form of tablets, capsules, 
injectables, ointments, etc. Usually conventional dosage forms produce wide range 
fluctuation in drug concentration in the blood stream and tissues with consequent 
undesirable toxicity and poor efficiency. The factors such as repetitive dosing and 
unpredictable absorption led to the concept of extended drug delivery systems. 
Advantages of extended release drug delivery: 
• Reduced frequency of drug. 
• Improved patient compliance. 
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• Reduced blood level oscillation characteristic of multiple dosing of conventional 
dosage forms. 
• Reduced amount of drug administration. 
• Maximum availability with a minimum dose. 
• Control of drug absorption, high blood level peaks that may be observed after 
administration of high availability drug can be reduced. 
• Safety margin of high potency drugs can be increased. 
•  Incidence of both local and systemic adverse effects can be reduced. 
• Increased reliability of therapy. 
Disadvantages of extended release drug delivery: 
• Administration of sustained release medication does not prompt termination of 
therapy. 
• The physician has less flexibility in adjusting dosage regimen. 
• Sustained release forms are designed for the normal population. 
 
8. IMMEDIATE RELEASE CONCEPT: 
           The tablet is intended to be released rapidly after administration, or the tablet is 
dissolved and administered, as solution. 
It is most common type and includes: 
 Disintegrating tablet 
 Chewable tablet 
 Sublingual tablet 
 Buccal tablet 
 Effervescent tablet 
 
9. MATRIX TABLETS 8: 
              A matrix is a uniform mixture of drug, excipients and polymer that is 
homogenously fixed in a solid dosage form. 
              Matrix devices consist of drug dispersed homogenously throughout a polymer 
matrix. In the model, drug in the outside layer exposed to the bathing solution is  
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dissolved first and then diffuses out of the matrix. This process continues with the 
interface between the bathing solution and the solid drug moving toward the interior. For 
this system rate of dissolution of drug particles within the matrix must be much faster 
than the diffusion rate of the dissolved drug leaving the matrix. 
        This system involves the following assumptions: 
• A pseudo steady state is maintained during drug release. 
• The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix. 
• The diffusion coefficient of drug in the matrix remains constant i.e., no change 
occurs in the characteristics of the polymer matrix. 
 
• The mechanism of release from these systems can be considered in two ways: 
a) Extraction of the medicament by a simple diffusion process through 
enveloping homogenous matrix. 
b) Leaching of the medicament by the bathing fluid, which is able to enter the 
drug-matrix please through pores, cracks and inter granular spaces. 
 
Table: Materials used as retardants in Matrix tablet formulations: 
 
Sl. No Matrix characteristics Materials 
      1. Insoluble, Inert Polyeythylene, polyvinyl chloride, 
Methylacrylate Co-polymer, Ethyl 
cellulose 
      2. Insoluble, Erodible Carnauba wax, stearyl Alcohol, 
Stearic acid, PEG 
      3. Hydrophilic Methyl cellulose, HPMC, sodium 
CMC. 
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10. HYPERTENSION: 
Blood pressure is usually classified based on the systolic and diastolic blood pressures. 
Systolic blood pressure is the blood pressure in vessels during a heart beat. Diastolic 
blood pressure is the pressure between heartbeats. A systolic or the diastolic blood 
pressure measurement higher than the accepted normal values for the age of the 
individual is classified as prehypertension or hypertension. 
Hypertension has several sub-classifications, including hypertension stage I, hypertension 
stage II, and isolated systolic hypertension. Isolated systolic hypertension refers to 
elevated systolic pressure with normal diastolic pressure and is common in the elderly. 
These classifications are made after averaging a patient's resting blood pressure readings 
taken on two or more office visits. Individuals older than 50 years are classified as having 
hypertension if their blood pressure is consistently at least 140 mmHg systolic or 
90 mmHg diastolic. Patients with blood pressures higher than 130/80 mmHg with 
concomitant presence of diabetes mellitus or kidney disease require further treatment. 
Hypertension is also classified as resistant if medications do not reduce blood pressure to 
normal levels. 
 
10.1 SIGNS AND SYMPTOMS 9, 10: 
Accelerated hypertension 
Accelerated hypertension is associated with headache, drowsiness confusion, vision 
disorders, nausea, and vomiting. These symptoms are collectively called hypertensive 
encephalopathy Hypertensive encephalopathy is caused by severe small blood vessel 
congestion and brain swelling which is reversible if blood pressure is lowered. 
Secondary hypertension 
Some additional signs and symptoms suggest that the hypertension is caused by disorders 
in hormone regulation. Hypertension combined with obesity distributed on the trunk of 
the body, accumulated fat on the back of the neck ('buffalo hump), wide purple marks on 
the abdomen (abdominal striae), or the recent onset of diabetes suggests that an  
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individual has a hormone disorder known as Cushing's syndrome. Hypertension caused 
by other hormone disorders such as hyperthyroidism, hypothyroidism, or growth 
hormone excess will be accompanied by additional symptoms specific to these disorders. 
For example, hyperthyroidism can cause weight loss, tremors heart rate 
abnormalities, reddening of the palms, and increased sweating Signs and symptoms 
associated with growth hormone excess include coarsening of facial features, protrusion 
of the lower jaw, enlargement of the tongue, excessive hair growth, darkening of the skin 
color and excessive sweating. Other hormone disorders like hyperaldosteronism may 
cause less specific symptoms such as numbness, excessive urination, excessive 
sweating, electrolyte imbalances and dehydration, and elevated blood alkalinity and also 
cause mental pressure. 
Medications: 
Several classes of medications, collectively referred to as antihypertensive drugs are 
currently available for treating hypertension. Reduction of the blood pressure by 5 mmHg 
can decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce 
the likelihood of dementia heart failure. and mortality from cardiovascular  disease. The 
aim of treatment should be to reduce blood pressure to <140/90 mmHg for most 
individuals, and lower for individuals with diabetes or kidney disease (some medical 
professionals recommend keeping levels below 120/80 mmHg). If the blood pressure 
goal is not met, a change in treatment should be made as therapeutic inertia is a clear 
impediment to blood pressure control. Co morbidity also plays a role in determining 
target blood pressure, with lower BP targets applying to patients with end-organ damage 
or proteinuria. 
The first line antihypertensive supported by the best evidence is a low dose thiazide-
based diuretic. 
Often multiple medications are needed to be combined to achieve the goal blood 
pressure. Commonly used prescription drugs include: ACE inhibitors, alpha 
blockers, angiotensin II receptor antagonists beta blockers, calcium channel blockers  
diuretics (e.g. hydrochlorothiazide), direct rennin inhibitors and Glyceryl trinitrates which 
has the activity of vasodilatation, thus controlling high blood pressure. 
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Some examples of common combined prescription drug include: 
A fixed combination of an ACE inhibitor and a calcium channel blocker. One example of 
this is the combination of perindopril and amlodipine. The efficacy of which has been 
demonstrated in individuals with glucose intolerance or metabolic syndrome.. 
Combinations of an ACE-inhibitor or angiotensin II–receptor antagonist, a diuretic and 
an NSAID (including selective COX-2 inhibitors and non-prescribed drugs such as 
ibuprofen) should be avoided whenever possible due to a high documented risk of acute 
renal failure.  
11. β -blockers 12: 
β-blockers or beta-adrenergic blocking agents, beta-adrenergic antagonists, beta-
adrenoreceptor antagonists or beta antagonists, are a class of drugs used for various 
indications. They are particularly for the management of cardiac arrhythmias, cardio 
protection after myocardial infarction (heart attack), and hypertension. 
 Indications for beta blockers include: 
 Angina pectoris 
 Atrial fibrillation 
 Cardiac arrhythmia 
 Congestive heart failure 
 Essential tremor 
 Glaucoma 
 Hypertension 
 Migraine prophylaxis 
 Mitral valve prolapse 
 Myocardial infarction 
 Phaeochromocytoma, in conjunction with α-blocker 
 Postural orthostatic tachycardia syndrome 
 Symptomatic control (tachycardia, tremor in anxiety and hyperthyroidism). 
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11.1 Beta blockers have also been used in the following conditions: 
 Acute aortic dissection 
 Hypertrophic obstructive cardiomyopathy 
 Marfan syndrome (treatment with propranolol slows progression of aortic dilation  
  and its complications) 
 Prevention of variceal bleeding in portal hypertension 
 Possible mitigation of hyperhidrosis 
 Social anxiety disorder and other anxiety disorders 
 
12. Congestive heart failure: 
Although beta blockers were once contraindicated in congestive heart failure as they have 
the potential to worsen the condition, studies in the late 1990s showed their efficacy at 
reducing morbidity and mortality in congestive heart failure. Bisoprolol, carvedilol and 
sustained-release metoprolol are specifically indicated as adjuncts to standard ACE 
inhibitor and diuretic therapy in congestive heart failure. 
Beta blockers are primarily known for their reductive effect on heart rate, although this is 
not the only mechanism of action of importance in congestive heart failure. Beta 
blockers, in addition to their sympatholytic B1 activity in the heart, influence the 
rennin/angiotensin system at the kidneys. Beta blockers cause a decrease in rennin 
secretion, which in turn reduce the heart oxygen demand by lowering extracellular 
volume and increasing the oxygen carrying capacity of blood. Beta blockers 
sympatholytic activity reduces heart rate, thereby increasing the ejection fraction of the 
heart despite an initial reduction in ejection fraction. 
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LITERATURE REVIEW 
 
 Gurvinder17 et al., examined the influence of critical formulation and processing 
variables as described in the AAPS/FDA Workshop ІІ reporter on scale-up of oral 
extended-release dosage forms, using a hydrophilic polymer hydroxypropyl 
methylcellulose (Methocel K100 LV). Granulation (1.5 Kg, 3000 units) were 
manufactured using a fluid-bed process, lubricated and tablets (100 mg metoprolol 
tartrate) were compressed on an instrumented Manesty D3B rotary tablets press. 
Dissolution tests were performed using USP apparatus 2, at 50 rpm in 900 ml phosphate 
buffer (pH6.8).  
 
 Al-Saidana 18 et al..,  carried out pharmacokinetic evaluation of oral controlled release 
formulation (guar gum-based three layer matrix tablets) containing highly soluble 
metoprolol tartrate has a model drug. The plasma concentration of metoprolol tartrate 
was estimated by reverse-phase HPLC. The pharmacokinetic parameters were 
calculated from the plasma concentration of metoprolol tartrate versus time data. The 
delayed Tmax lower Cmax decreased  un altered bioavailability and prolonged indicated a 
slow and prolonged release of metoprolol tartrtate from guar gum three-layer matrix 
tablets in comparison with the immediate release tablet dosage form. 
 
 Bjoern19 et al.., investigate the effects of beta 1-blockade on left ventricular (LV) size 
and function for patients with chronic heart failure. Large-scale trials have shown that a 
marked a decrease in mortality can be obtained by treatment of chronic heart failure 
with beta-adrenergic blocking agents. Possible mechanisms behind this effect remain 
yet to be fully elucidated. In this randomized, placebo-controlled and double-blind 
study to the metoprolol CR/XL randomized intervention trial in Heart Failure (MERIT-
HF). 
 
 Narendra20 a et al., evaluated the effect of formulation variables on release properties 
and bio-adhesive strength in development of three layered buccal compact containing 
highly water-soluble drug metoprolol tartrate (MT) by statistical optimization 
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technique. Formulations were prepared based on rotatable central composite design 
with peripheral polymer ratio (carbopol 934 P HPMC 4KM) and core polymer ratio 
(HPMC 4KM:sodium alginate) as two independent formulation variables. The three 
layered buccal compact comprises peripheral layer, core layer and backing layer. Four 
dependent (response) variables were considered: bio-adhesion force, percentage MT 
release at 8h, T 50% (time taken to release 50% of drug) and release exponent (n). The 
release profile data was subjected to curve fitting analysis for describing the release 
mechanism of MT from three layered buccal compact. The main effect and interaction 
terms was quantitatively evaluated by quadratic model. The decrease in MT release was 
observed with an increase in both the formulation variable and as the carbopol:HPMC 
ratio increases the bio-adhesive strength also increases.  
 
 Jozesef21 et al., investigated the drug release and FT-IR characteristics of metolose 
patches the changes of metolose SM 4000 (methylcellulose) and metolose 90SH 
(hypromellose) proportions. FT-IR spectroscopy measurements were performed in 
parallel with the metoprolol tartrate release study to track the effect of the composition 
on the drug release. Linear relationship was found with good correlation between the 
logarithm of time interval necessary to release 63.2% of metoprolol tartrate (dvalues) 
and the peak area measured within the characteristic FT-IR wavenumbers of patches.  
 
 Milton22 et al.,  indicated carvedilol exerts multiple antiadrenergic effects in addition to 
β1receptor blockade, the recently completed carvedilol or metoprolol europian trial 
(COMET), which showed that carvedilol ( 25 mg twice daily) reduced mortality by 
17% when compared with metoprolol ( 50 mg twice daily ), a result that was consistent 
with the differences seen across earlier controlled trials with β  blockers in survivors of 
an acute myocardial infarction and in patient with chronic heart failure. These analyses 
suggest that the observed difference in the mortality effects of metoprolol and 
carvedilol is not related to a difference in the magnitude or time course of their β1 
blocking effects but instead reflect antiadrenergic effects of carvedilol in addition to β1  
blockade.  
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 Alan23 et al., used extended Cox regression to examine the association between receipt 
of different blockers and risk of readmission for HF after adjustment for potential 
confounders. During follow-up, there were 3,234 person-years of exposure to blockers 
(39.3% atenolol, 42.0% metoprolol tartrate, 12.3% carvedilol, and 6.4% other). Crude 
12-month rates of readmissions for HF were high overall (42.6 per 100 person-years). 
After adjustment for potential confounders, cumulative exposure to each  blockers, and 
propensity to receive carvedilol compared with atenolol, adjusted risks of readmission 
were not significantly different for metoprolol tartrate (adjusted hazard ratio 0.95, 95% 
confidence interval 0.85 to 1.05) or for carvedilol (adjusted ratio 0.92, 95% confidence 
interval 0.74 to 1.14). 
 
 Alaa24 et al.,   presented different spectrophotometric and HPTLC densitometric  for the 
simultaneous determination of lisinopril and hydrochlorothiazide in pharmaceutical 
tablets.  
 
 Hillaert25 et al., studied the capability of the capillary zone electrophoretic (CZE) and 
micellar electrokinetic capillary chromatographic (MEKC) methods to simultaneously 
separate hydrochlorothiazide and six angiotension–II- receptor antagonists (ARA–II): 
candesartan, eprosartan  mesylate, irbesartan, losartan potassium, telmisartan, and 
valsartan. The CZE and MEKC methods are suitable for the qualitative and quantitative 
determination of combined HCT/ARAΠs in pharmaceutical formulations. Depending 
on the ARA–II at least one of the two methods can be used for each combination.  
 
 Ndindayino26 et al., evaluated the bioavailability of hydrochlorothiazide (HCT) from 
moulded isomalt–based tablets after oral administration of 50 mg HCT  as an oral 
moulded tablet and as a lozenge, in comparison with a conventional tablet formulation. 
The relative bioavailability of the moulded tablet administered as a lozenge and as an 
oral tablet was 106.29, 30.9% and 89.49, 25.9%, respectively, in relation to the 
conventional tablet formulation.  
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 Sam27 et al.., studied the influence of different formulation and process parameter on 
the characteristics of lyophilized oral dosage forms.   Maltodextrins, gelatins, xanthan 
gum and hydroxyethylcellulose were evaluated as excipient in the formulation of 
freeze-dried tablets. The resulting were analysed for mechanical strength, porosity, 
disintegration time and residual moisture. Scanning electron micrographs of the fracture 
plane of the tablets were taken. Additionally dissolution tests were performed on 
lyophilized tablets containing hydrochlorothiazide as a model drug. E 
 
 S. Mohamed Halith28 et al., Formulated and evaluated of bilayer tablets of amlodipine 
besilate and metprolol succinate and have done on DSC studies  formulation and 
compare to pure compound Heat flow rates were measured over a temperature range of 
30°C - 300°C at a heating rate of 15°C/min for Amlodipine Besilate pure drug, placebo 
and tablet samples. Similarly temperature range of 25°C- 250°C at a heating rate of 
5°C/min was used for Metoprolol Succinate pure drug, placebo, and tablet samples. 
 
 Vaijanath G. 29 et al., Simultaneous determined  metoprolol succinate and amlodipine 
besylate in pharmaceutical dosage form by HPLC. The mobile phase consisting of 
buffer (aqueous triethylamine pH 3) and acetonitrile in the ratio of 85: 15 (v/v) at a flow 
rate of 1.0 ml/min was used. The method was validated according to the ICH guidelines 
with respect to specifity, linearity, accuracy, precision and robustness. 
 
 Vishnu P.Choudhari30 et al., compared in vitro, newly formulated controlled-release 
tablets with standard commercial tablets (MetXL50).The prepared matrix tablets 
showed good mechanical properties (hardness and friability). Hydroxypropyl methyl 
cellulose and Alginate-based tablet formulations showed high release-retarding 
efficiency, and good reproducibility. FTIR study suggesting that HPMC K15M and 
Alginate are good candidates for preparing modified release tablet formulations 
Metoprolol succinate. 
 Prasada Rao31 et al., developed a simple, rapid and selective HPLC method developed 
for quantization of Amlodipine Besylate and Metoprolol succinate from bulk drug and 
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pharmaceutical formulations using a mobile phase consisting mixture of 0.02 M 
phosphate buffer solution and Acetonitrile as 80:20 at the flow rate of 1 mL/min. An 
Inertsil ODS-CV column was used as stationary phase. The retention time of 
Amlodipine Besylate and Metoprolol succinate were 3.92 and 10.43 respectively.  
 Brijesh32 et al, developed a simple, sensitive and rapid reverse phase HPLC method for 
the simultaneous analysis of metoprolol succinate and hydrochlorothiazide in a solid 
dosage form. The drugs were analysed by a reverse phase C-18 column using 50mM di-
sodium hydrogen phosphate:methanol:acetonitrile in a ratio of 525:225:250 as mobile 
phase. The flow rate was 1 ml/min and the compounds were detected by a UV-detector 
at 222 nm at a column temperature of 24 ± 2 ºC. The method was statistically validated 
for linearity and accuracy. 
 R. K. Seshadri33 et al., developed simple ultra performance liquid chromatographic 
(UPLC) method developed for the simultaneous estimation of Metoprolol (MT), 
Atorvastatin (AT) and Ramipril (RM) from capsule dosage form. The (4.6 mm x 50 
mm, 1.8 µm) column with a mobile phase consisting of 0.06% ortho phosphoric acid in 
water having an ion pair reagent, 0.0045 M Sodium lauryl sulphate as buffer, at ratio of 
buffer. Acetonitrile (50:50 v/v), at 55°C column temperature with a flow rate of 1.0 
ml/min. The method was found to be rugged and robust and can be successfully used to 
determine the three drugs and its combinations. 
 V.Rajamanickam34 et al., developed and validate a economic, rapid reversed-phase 
high-performance liquid chromatographic method for the quality control of Metoprolol 
succinate and amlodipine besylate in pharmaceutical preparations with lower solvent 
consumption along with the short analytical run time leads to an environmentally 
friendly chromatographic procedure that allows the analysis of a large number of 
samples in a short period of time. 
 N.N.Rajendran35 et al.,  investigated the effect of a novel drug- drug solid dispersion 
approach on the dissolution of hydrochlorothiazide in a fixed dose combination with 
Losartan potassium Solid dispersions by differential scanning calorimetry, x-ray 
diffractometry and dissolution tests and the results were compared with that of pure 
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drugs and physical mixtures. Solid dispersion as well as physical mixture were then 
compressed into tablets and evaluated for physicochemical, stability and dissolution 
characteristics and the results compared with commercial tablets. 
 Rekha Gangola36 et al., studied the combination of Hydrochlorothiazide and 
Telmisartan is useful in treatment of mild to moderate hypertension, and is well 
tolerated with a lower incidence of cough than ACE inhibitors. The marketed tablets 
contain Telmisartan and Hydrochlorothiazide in ratio of 40:12. The widespread use of 
these drugs in combination, necessitates development of analytical methods for their 
simultaneous estimation. Several analytical procedures have been proposed for the 
quantitative estimation of Telmisartan and Hydrochlorothiazide separately and in 
combination with other drugs. 
 Padma priya S37 et al., prepared solid dispersions in proportions similar to commercial 
preparations of hydrochlorothiazide and captopril (HCT‐CAP) combination. The solid 
dispersions were evaluated for in vitro dissolution characteristics and the results were 
compared with that of physical mixtures of HCT‐CAP and pure hydrochlorothiazide. 
The dissolution rate of hydrochlorothiazide from solid dispersions was found to be 
faster than that of physical mixtures and pure drug. 
 Messerli38 et al., evaluated the antihypertensive efficacy of hydrochlorothiazide 
(HCTZ) by ambulatory blood pressure (BP) monitoring. Fourteen studies of HCTZ 
dose 12.5 to 25 mg with 1,234 patients and 5 studies of HCTZ dose 50 mg with 229 
patients fulfilled the inclusion criteria. The antihypertensive efficacy of HCTZ in its 
daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP 
measurement is consistently inferior to that of all other drug classes. Because outcome 
data at this dose are lacking,  
 D.E. Clarke39 et al., studied the acute and chronic effects of hydrochlorothiazide on 
adrenergic neuronal and receptor function in the isolated perfused dog mesenteric 
arteries have been characterized. Hydrochlorothiazide, 2.7 mg/min for 90 min, perfused 
directly into the arteries, failed to alter adrenergic mechanisms. Chronic oral treatment 
of dogs with hydrochlorothiazide, 10 mg/kg/day, for 6 months enhanced the frequency-
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response curve to periarterial nerve stimulation without affecting the vasoconstrictor 
responses to norepinephrine. 
 S. G. Chrysant40 et al., reported on long-term efficacy, safety, and tolerability data 
from this third-year extension trial in which patients received the combination of 
valsartan 80 mg and Hydrochlorothiazide 12.5 or 25 mg for at least 2 years. 
 M. Lusina41 et al., investigated how the quality of a drug product changes with time 
under the influence of environmental factors, to establish a shelf life for the product and 
to recommend storage conditions of Hydrocholorothiazide tablets, OPA/Al/PVC//Al 
blisters were found to provide adequate protection for the product. Based on the first 12 
months of the formal stability study, a shelf life of 24 months. 
Losartan/hydrochlorothiazide tablets in OPA/Al/PVC//Al blisters are demonstrated to 
be chemically, physically and microbiologically stable.  
 D.S. Desai,42 et al.,  studied  hydrochlorothiazide (HCTZ) drug substance is known for 
its excellent solid-state stability, it can undergo hydrolysis with the formation of 
formaldehyde and 4-amino-6-chloro-l,3 benzenedisulfonamide (free amine). The 
degradation of HCTZ in a dosage form is undesirable due to the tight limits that need to 
be set for the free amine content. It was hypothesized that the mechanism of 
degradation of HCTZ in the presence of PVP and/or Pluronic ® F68 was due to 
solubilization of the HCTZ by these excipients in the moisture present in tablets, 
followed by its hydrolysis. 
 Y.S.R. Krishnaiah43 et al., designed oral controlled drug delivery systems for highly 
water-soluble drugs using guar gum as a carrier in the form of a three-layer matrix 
tablet of Metoprolol tartrate. Matrix tablets containing either 30 (M1), 40 (M2) or 50% 
(M3) of guar gum by wet granulation technique using starch paste as a binder. Three-
layer matrix tablets of metoprolol tartrate by compressing on both sides of guar gum 
matrix tablet granules of metoprolol tartrate M1, M2 or M3 with either 50 (TL1M1, 
TL1M2 or TL1M3) or 75 mg (TL2M1, TL2M2 or TL2M3) of guar gum granules as 
release retardant layers. Both the matrix and three-layer matrix tablets were evaluated 
for hardness, thickness, drug content uniformity, and subjected to in vitro drug release 
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studies. The guar gum, in the form of three-layer matrix tablets, is a potential carrier in 
the design of oral controlled drug delivery systems for highly water-soluble drugs such 
as metoprolol tartrate. 
 
 Mothilal M44 et al.,  formulated ODDS for metoprolol Succinate using different 
concentrations of mannitol, by wet granulation technique. The tablets were coated by 
dip coating with cellulose acetate. Stainless steel drill pins were used to make an orifice 
on the tablets. Tablet thickness, hardness, weight variation and drug content analysis, 
drug release study were performed. Orifice diameter was examined using scanning 
electron microscopy (SEM). With increase in osmogen content and bore size, rate of 
drug release were found to be increasing an optimum concentration of osmogen and 
bore size to give a zero order release was identified. 
 
 Alexander45  et al.,. evaluated and compared the in-vitro and in-vivo erosion profiles of 
two tablet formulations primarily consisting of hydroxypropylmethylcellulose (HPMC) 
and lactose. HPMC polymer percolation threshold in controlled release matrix 
formulations: 20 and 40% (w/w). In-vitro erosion behavior was studied using traditional 
gravimetric and scintigraphic methods, with radiolabel led charcoal used as a marker to 
quantify erosion profiles in scintigraphic studies. Tablets containing 40% (w/w) HPMC 
(polymer level above percolation threshold) demonstrated robust in-vivo performance 
and showed stronger correlation with in-vitro erosion profiles. The matrix formulation 
with a lower concentration of HPMC and higher lactose concentration is more likely to 
perform poorly in the in-vivo environment. 
 
 Chuan-Yu46 et al., described the compaction behavior of binary mixtures and bilayer 
tablets of two common pharmaceutical excipients, microcrystalline cellulose and lactose. 
The delamination phenomena during the manufacturing of bilayer tablets and fracture 
patterns of tablets subjected to diametrical compression are examined using X-ray 
computed to monography. The mechanical properties of binary and bilayer tablets of the 
same composition were also determined and compared. 
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 Jakkie47 et al., reported the effect of V-mixer size on the mixing of magnesium stearate 
with directly compressible microcrystalline cellulose and evaluated the mixing process 
and compare the performance of the mixers, the extent of the decrease in tablet crushing 
strength was measured. The kinetics of the decrease in crushing strength were best 
described by the sum of two separate processes, one first-order and the other second-
order. Overall, the faster second-order process dominated mixing because the first-order 
rate decreased, while the second-order rate increased. with an increase in mixer volume. 
Results showed that the limiting crushing strength increased with an increase in mixer 
size and that there was a linear relationship between the limiting crushing strength and 
the logarithm of the volume of the mixer. A decrease in mixer load from 33 to 18% also 
led to an decrease in tablet strength. 
 
 Jenny Herder48 et al.,  studied the properties of the granules and the tablets fall into two 
groups according to whether the molecular weight of the polymer is high or low. The 
granules of low molecular weight were smaller and more compact, with better flow 
properties but with less tensile strength of the compacts, whereas the opposite was valid 
for granules of high molecular weight. The explanation for these differences is linked to 
the proposed granulation mechanism of HPMC, in which the properties of the gel layer 
are important. The dominant factors governing the properties are the molecular weight 
and, to lesser extent, the degree of substitution. 
 
 Calum49 et al., developed bilayer mucoadhesive tablets of Nicotine evaluated to 
determine the suitability of the formulation as a Nicotine replacement product to aid in 
smoking cessation. A combination of 20% w/w carbopol 934 and 20% w/w 
Hydroxypropylcellulose was found to provide suitable adhesion and controlled drug 
release. The formulation of bilayer tablet containing the adhesive controlled release layer 
and a fast releasing layer provided an initial burst release of drug followed by the 
controlled release for a period of upto 4 hours. 
 
 Miyazaki50 et al., developed potential of bilayer tablets containing 1:4, 1:1 and 4:1 
weight ratios of pectin and HPMC for the sustained release of Diltiazem by sublingual 
                                                                                                          LITERATURE REVIEW 
 
Dept of pharmaceutics, K.M College of Pharmacy, Madurai. Page 22 
 
administration has been investigated. An in vitro sustained release of Diltiazem over 5 
hours was achieved with bilayer tablets composed of a drug-free ethyl cellulose layer in 
addition to the pectin/HPMC layer containing drug. Bioavailability of Diltiazem was 2.5 
times than achieved by oral administration for single layer tablets and 1.8 time for the 
bilayer tablets. 
 
 Anil Chaudhary51 et al., prepared microporous bilayer osmotic tablet bearing 
dicyclomine hydrochloride and diclofenac potassium by using a new oral drug delivery 
system for colon targeting. The tablets were coated with microporous semi permeable 
membrane and enteric polymer using conventional pan-coating process. The number of 
pores was dependent on the amount pore former in the semi permeable membrane. In 
vitro dissolution results indicated that system showed acid resistance, timed release was 
able to deliver drug at an approximate zero order up to 24 hour.  
 
 Carmen52 et al., prepared new buccal delivery devices comprising a drug containing 
mucoadhesive layer and a drug free backing layer, by two different methods. The 
mucoadhesive layer was composed of a mixer of drug and chitosan, with or without an 
anionic cross linking polymer (polycarbophill, sodium alginate, gellan gum), and the 
backing layer was made of ethyl cellulose. The double layered structure design was 
expected to provide drug delivery in a unidirectional fashion to the mucosa and avoid loss 
of drug due to wash out with saliva. Using nifedipine and propranolol hydrochloride as 
slightly and highly water soluble model drugs, respectively, it was demonstrated that 
show promising potential for use in controlled delivery of drugs to the oral cavity. The 
uncrosslinked chitosan containing devices absorbed a large quantity of water, jelled and 
then eroded allowing drug release. The bilaminated films shows a sustained drug release 
in a phosphate buffer (pH 6.4) 
 
 Yong53 et al., used electrochemically synthesized conducting polymer polypyrrole (PPy) 
film on gold electrode surface was used as a novel support for bilayer lipid membrane 
(BLMs). The   formation of PPy supported bilayer lipid membranes (s-BLMs) is 
dependent on  the chemical structure of the lipid use. 
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 Mina54 et al. developed a gastro retentive controlled release drug delivery system with 
swelling, floating and adhesive properties by using hydroxyl propyl methyl cellulose 
(HPMC K15M) and/or sodium alginate (Na alginate) as release-retarding polymer(s) and 
sodium bicarbonate (NaHCO3) or calcium carbonate (CaCO3) as a gas former. Swelling 
ability, floating behavior, adhesion period and drug release studies were conducted in 
0.1N HCl (pH 1.2) at 37±0.5˚C.  
 
 Panagiotis barmpalexis55 et al., investigated nimodipin-polyethylene glycol solid 
dispersions for the development of effervescent controlled release floating tablet 
formulation.  
 
 Fridrun Podczecka56 et al., determined the tensile strength of bilayer tablets made from 
different grades of microcrystalline cellulose. While these grades are chemically 
identical, they differ significantly in their particle size distribution and in their 
mechanical properties such as young’s modules of elasticity. Both particle size and 
Young’s modules of elasticity influenced the overall strength of layered tablets. If the 
material forming the lower layer was more elastic, then the beam strength was reduced 
due to tension introduced into the system, acting especially at the layer interface and 
potential causing partial or complete delamination. 
 
 Hema57 et al., described a modulated release, multiunit oral drug delivery technology 
using a system based on ionic interactions of anions of salts with quaternary ammonium 
ions of the ammoniomethacrylate  polymer. The system consisted of a drug layered, 
EUDRAGIT NE-coated salt core which was further coated with EUDRAGIT RS. The 
relative effects of different anions on the polymer permeability have been investigated by 
studied their influence on the in vitro drug release. A prototype formulation of metoprolol 
succinate using this technology was developed and the drug release from the formulation 
was adjusted to have a release profile which would match the circadian rhythm i.e a 
higher amount of drug would be available after an initial lower release (accelerated type 
of release). 
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 Jeffrey58 et al.,.  studied Beta blockers which are known to suppress renin release in 
hypertension and in patient taking angiotensin converting enzyme (ACE) inhibitors. 
The effect of additional blockade on neurohumoral modulation in patients with severe 
heart failure (HF) who received ACE inhibitors.  
 
 Yogesh59 et al., investigated the effect of molecular characteristic  co polymers viz 
pluronic P103, P123, and F127 on micellar behavior and solubilisation of a diuretic 
drug, hydrochlorothiazide (HCTZ), the critical micellization temperatures (CMTs) and 
size for empty as well as drug loaded miscells are reported. The CMTs and miscells 
depended on the hydrophobicity and molecular weight of the copolymer; a decrease in 
CMT and increase in size was observed on solubilization.  The solubilization of the 
drug hydrochlorothiazide (HCTZ) in the block copolymer nano aggregates at different 
temperatures (28, 37, 45˚ C), pH (3.7, 5.0, 6.7) and in the presence of added salt (NaCl) 
was monitored by using UV-Visble spectroscopy and solubility data were used to 
calculate the solubilization characteristics; micelle water partition coefficient (P) and 
thermodynamic parameters of solubilization viz. Gibbs free energy (Gs˚), enthalpy 
(Hs˚), and entropy (Ss˚). The solubility of the drug in copolymer increases with trend: 
P103> P123> F127.  
  
 Ajit Kulkarni60 et al., Developed of regioselective bilayer floating tablets of Atenolol 
and Lovastatin for biphasic release profile. In DSC studies the tablet was ground to 
powder and a 1-2 mg sample was hermetically sealed in an aluminum pan and heated at 
a constant rate of 10°C/min, over a temperature range of 50-200 °C. Inert atmosphere 
was maintained by purging nitrogen gas at a flow rate of 20 ml/min.  
 
 Sapna N61 et al., studied once daily sustained release tablets of venlafaxine, a novel 
antidepressant, to know the extended release tablet from time of administration. 
 
  Velasco-De-paola62 et al., studied  dissolution kinetics of controlled-release tablets 
containing Propranolol Hydrochlororide. The physical properties of the tablets were 
determined. Dissolution tests were performed in capsules containing the raw material 
                                                                                                          LITERATURE REVIEW 
 
Dept of pharmaceutics, K.M College of Pharmacy, Madurai. Page 25 
 
using the following dissolution media: (A) distilled water, (B) simulated gastric juice 
without enzymes, and (C) simulated enteric juice without enzymes. A dissolution test 
was also performed for simulated samples (tablets) using distilled water as the 
dissolution medium. 
 
 Gummudavelly Sandeep63 et al., studied extended release or controlled release 
formulation are its ability to maintain ß1 selectivity over 24hours, but with relative lack 
of peak plasma concentration, thus avoiding decreased clinical ß 1 selectivity as seen at 
high plasma concentration. Release kinetics evaluated by using USP-22 (Paddle) 
dissolution apparatus. In-vitro release study showed that ERT10 for 25mg label claimed 
were well suited to extend release for 20 hours with zero order release. In-vitro swelling 
studies revealed by Korsmeyer-Peppa’s model that, the drug release governed by 
swelling of polymer and it is anomalous diffusion or non-fickian transport. 
 A. Streubel64 et al., developed new multi-layer matrix tablets to achieve bimodal drug 
release profiles (fast release /slow release / fast release). Hydroxypropyl 
methylcellulose acetate succinate (HPMCAS, type MF) as a matrix former, because it is 
water-insoluble at low, and water-soluble at high pH values. The addition of a fourth, 
drug-containing and fast disintegrating initial dose layer yielded the desired bimodal 
drug release patterns. The process and formulation parameters affecting the resulting 
release rates using theophylline and acetaminophen as model drugs. 
 
 K.G. Wagner65 et al.., studied enteric coated bisacodyl pellets were compressed into 
divisible disintegrating tablets on a high speed rotary tablet press. The degree of pellet 
damages was examined via the bisacodyl dissolution during the acid treatment of' the 
drug release test for enteric coated articles according to USP. The damages depended 
on the type of ®ller-binder used and settings of the tablet press. Avicel PH 101 proved 
to be the most suitable ®ller-binder, effecting homogeneous distribution of the pellets 
within the tablets, as could be shown by image analysis of coloured pellets. Reducing 
the proportion of pellets to 60% per tablet, less than 10% of bisacodyl were released 
within 2 h during acid treatment thus full flling the requirements of the USP. 
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 Rashmi Dahima66 et al. increased the solubility and dissolution rate of amlodipine 
besylate by the preparation of its solid dispersion with cross povidone using solvent 
evaporation method. Drug polymer interactions were investigated using differential 
scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR). 
Surface morphology of solid dispersion particle determined by SEM study. Dissolution 
rate of solid dispersion was determined in 0.01 N HCl at 75 rpm. The obtained results 
showed that dispersion of the drug in the polymer considerably enhanced the 
dissolution rate. It revealed that crosspovidone in solid dispersion itself act as 
superdisintegrant and binder and an optimum concentration of a pregelatinized starch is 
required for obtaining rapidly disintegrating tablets. The potential of experimental 
design in understanding the effect of the formulation variables on the quality of mouth 
dissolving tablets containing solid dispersion of a hydrophobic drug. 
 
 Naeem67 et al., developed and characterized bilayer tablet formulations of tramadol 
HCl (TmH) and acetaminophen (AAP) microparticles. Coacervation via temperature 
change the encapsulated method used for the preparation of the microparticles, with 
ethyl cellulose (EC) of medium viscosity as the polymer for extending drug release. 
FTIR, XRD, DSC and TGA data for the formulations indicate good compatibility and 
stability. Furthermore, accelerated stability studies confirmed the stability of the 
formulations. Controlled drug release from the microparticles and bilayer tablets was 
observed for 8 h and 12h, respectively. Microencapsulated TmH and AAP can be 
developed into suitable bilayer tablets that are stable and capable of releasing the drugs 
over 12h. 
 
 L. Yang68 et al., formulated components were poly(ethylene oxide) (PEO), lactose, and 
theophylline. Results indicate that the formulation of each layer and the combined 
triple-layer tablet exhibited similar compression behavior, and the consolidation 
mechanism was shown to follow predominantly plastic deformation as evidenced by the 
shape of Heckel plots and high SRS (Strain Rate Sensitivity) values. A triple-layer 
tablet formulation necessitates careful selection of plastic, brittle, and other desirable 
components to ensure comparable compactibility profiles. 
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 Rakhee A. Surana69 et al., formulated Phenyl propanolamine Hydrochloride sustained 
release pellets. Uni Glatt fluid bed processor (Glatt, Germany) was used for drug 
solution layering and also for sustained release coating.By using Hypromellose E5, 
Ethylcellulose 10cps and Ethylcellulose 45cps polymers in combination. Polymeric 
solution was prepared by dissolving polymers into different solvents in different 
proportion to form clear coating solution. The pellets were evaluated for appearance, 
shape and size analysis, density, assay, content uniformity, in-vitro drug release studies, 
stability study and kinetic study. The optimized batches were charged for stability at 
40°C and 75% RH for 2 months. The drug release studies were repeated after storage 
for 2 months at conditions like room temperature (RT) and 40ºC and 75% RH.  
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                             Aim of the present investigation 
The present investigation relates to the development of Bilayer dosage form 
containing combination of sustained and immediate release layer by using Metoprolol 
Succinate and Hydrochlorothiazide respectively for the treatment of Hypertension. 
Metoprolol Succinate is a beta selected adrenoreceptor blocking agent, for oral 
administration in the treatment of hypertension, anginapectoris and heart failure. It has a half 
life of 3 to 7 hours. Metoprolol reduces the force of contraction of heart muscle and there by 
lowers blood pressure. By reducing the heart rate and the force of muscle contraction, 
Metoprolol reduces the need for oxygen by heart muscle. Heart pain (angina pectoris) occurs 
when oxygen demand of the heart muscle exceeds the supply of oxygen, the reducing the 
demand for oxygen, is helpful in treating heart pain.    
Metoprolol Succinate extended-release tablet is a beta-1 (cardio-selective) 
adrenoceptor-blocking agent formulated to provide controlled and predictable release of 
metoprolol. Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive 
agent, which promotes natruresis by acting on the distal renal tubule. 
          Hydrochlorothiazide is a first line diuretic drug of the thiazide class that acts by 
inhibiting the kidney’s ability to retain water. This reduces the volume of the blood, 
decreasing lower peripheral vascular resistance.  
The combination product more effective than monotherapy with the individual 
components but the combination product allows a low-dose multidrug regimen as an 
alternative to high-dose monotherapy, thereby, minimizing the likelihood of dose-related 
side-effects 
The purpose of this study was to develop a bilayer tablet of sustained release of 
Metoprolol Succinate using Hydroxy propyl methyl cellulose as hydrophilic polymer and 
immediate release of Hydrochlorothiazide Direct compression method. 
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Finally intra batch reproducibility and stability study to be carried out for the selected 
bilayer tablets. 
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4. Plan of work 
1. Preformulation study: 
1.1 Raw material analysis of Metoprolol Succinate. 
1.2 Raw material analysis of Hydrochlorothiazide. 
1.3 Drug –Excipient compatibility studies. 
1.4 Physical observation.  
1.5 FT-IR. 
2. Formulation and evaluation of Bilayer tablets: 
2.1 Formulation of sustained release granules of Metoprolol Succinate. 
2.2 Formulation of Immediate-release granules of Hydrochlorothiazide. 
2.3 Evaluation of sustained release granules of Metoprolol Succinate. 
2.4 Evaluation of immediate release granules of hydrochlorothiazide. 
2.5 Compression of bilayer tablets. 
2.6 Evaluation of compressed Bilayer tablets. 
2.7 Packing of Bilayer tablets (Blister packing). 
3. Optimized formulation was subjected to the following studies: 
3.1 Release kinetic study for Bilayer tablet. 
3.2 In vitro dissolution study for different formulations. 
            3.3 Stability study for selected formulation. 
            3.4 Differential Scanning Calorimetry (DSC) studies.  
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5. Materials and Instruments 
 Table: 5.1 Materials and methods 
Sl. No Materials 
 
Manufacturers/ suppliers 
1 Metoprolol Succinate Aarthi Drugs Ltd, Mumbai. 
2 Hydrochlorothiazide Benzochem Life Science, 
Mumbai 
 
3  
Hydroxy propyl methyl cellulose. 
(HPMC K100M) 
Dow Chemicals, Canada 
4  
Hydroxypropylmethylcellulose. (HPMC 
K4M) 
Dow Chemicals, Canada. 
5 Lactose DCL 11 
 
DMV Holland 
6 Maize starch 
 
Vijaya Enterprises, 
Mumbai. 
7 Povidone (PVP K-30) 
 
Basf, Germany. 
8 Carbomer 971P 
 
Corel Pharma, Gujarat. 
9 Ethyl cellulose 20cps 
 
Basf, Germany. 
10 Microcrystalline cellulose IP (Avicel 
pH102) 
 
RanQ Remedies, Mumbai. 
11 Microcrystalline cellulose IP (Avicel 
pH101) 
 
RanQ Remedies, Mumbai. 
12 Colloidal silicon dioxide    (Aerosil) 
 
Cobot Sanmar, USA. 
13 Talc 
 
Aravelli pvt. Ltd., 
New Delhi. 
14 Magnesium stearate 
 
Amshi Drug and 
Chemicals, Gujarat. 
15 Colour:Brilliant blue lake 
 
Roha Dye Chem, Mumbai. 
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     Table: 5.2 Manufacturing Equipments 
 
Sl. No Equipments Manufacturers/ Suppliers 
1 Moisture  balance Sartorius, Germany 
2 Vibratory sifter Bectochem, Mumbai. 
3 Planetary Mixer (vertical 
main drive) Bectochem, Mumbai. 
4 Hexagonal blender Bectochem, Mumbai. 
5 Rapid mixer Granulator Bectochem, Mumbai. 
6 Fluidized bed dryer Bectochem, Mumbai. 
7 Tray drier Micro, S.B.Panchal and Co, India 
8 Multi Mill Bectochem, Mumbai. 
9 Double Rotary Compression Machine (27 station) Cadmach, India. 
10 Dehumidifier Tropical nortec, India 
11 Vernier caliper Mitutoyo corps, Japan 
12 Blister Packing machine Lab module, India 
13 Photostability and humidity 
chamber Thermolabs India Ltd. 
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Table: 5.3 List of Instruments: 
 
Sl. No Instruments Manufacturers/ Suppliers 
1 Electronic weighing balance Shimadzu corporation, Japan 
2 pH Meter Mettler, Toledo, India. 
3 Tap Density apparatus, ETD-1020 Electro lab, India. 
4 Hardness tester Monsanto , India 
5 Friability Test Apparatus, ET-2 Electro lab, India. 
6 Dissolution Apparatus, TDT-08L, Electro lab, India. 
7 FT-IR Spectrophotometer 8300 Shimadzu corporation, Japan 
8 Differential scanning colorimetry  DSC Q2000 V24.4 build 114  
9 UV- Visible Spectrophotometer (UV-1601) Shimadzu corporation, Japan 
10 HPLC with PDA detector Waters HPLC, India. 
11 Refrigerator Whirlpool, India 
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  Table: 5.4 List of Reagents 
 
Sl. No Reagents/ chemicals 
 
Manufacturers/suppliers 
1 
Potassium dihydrogen ortho 
phosphate AR 
 
Rankem, New Delhi. 
2 Sodium hydroxide AR 
 
RankemNew Delhi. 
3 Acetonitrile HPLC 
 
Merck Canada. 
4 Methanol HPLC 
 
Merck, Canada. 
5 
Sodium dihydrogen ortho 
phosphate AR 
 
Rankem, New Delhi. 
6 Ortho phosphoric acid AR 
 
Rankem, New Delhi. 
7 Hydrochloric acid AR 
 
Rankem, New Delhi 
8 Whatman filter paper 
 
Sartourious 292A, North America. 
9 0.45 µ filter paper 
 
Millipore, Canada. 
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5.5 Drug profile 
 5.5.1 Metoprolol succinate  USP71 
Molecular formula: (C15H25NO3)2,C4H6O4 
 Molecular weight: 652.8 
Molecular structure: 
                                       
                                                                                               
 
Chemical Name: 
Description:  A white to off-white powder 
Solubility: 
Freely soluble in water; soluble in methyl alcohol; sparingly soluble in 
alcohol; slightly soluble in isopropyl alcohol 
Melting point: 120°C (240°F) 
Therapeutic category:  Antihypertensive 
General Description: 
Metoprolol Succinate extended-release tablets are a beta1-selective (cardio 
selective) adrenoceptor blocking agent, for oral administration, available as 
extended release tablets. Metoprolol Succinate extended-release tablets have been 
formulated to provide a controlled and predictable release of Metoprolol for once-
daily administration 
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Mode of action: 
Metoprolol Succinate, is the selectively blocks beta1-adrenergic receptors in the 
heart and vascular smooth muscle. The effects of Metoprolol Succinate in treating 
hypertension include a negative chronotropic effect that decreases heart rate at rest and 
after exercise; a negative inotropic effect that decreases cardiac output; reduction of 
sympathetic outflow from the CNS; and suppression of renin release from the kidneys.  
Pharmacokinetics: 
Metoprolol is readily and completely absorbed from the gastrointestinal tract but 
is subject to considerable first-pass metabolism, with a bioavailability of about 50%. Peak 
plasma concentrations vary widely and occur about 1.5 to 2 hours after a single oral dose. 
It is moderately lipid-soluble. Metoprolol is widely distributed; it crosses the blood brain 
barrier and the placenta, and is distributed into breast milk. It is about 12% bound to 
plasma protein. It is extensively metabolized in the liver, mainly by the cytochrome P450 
isoenzyme CYP2D6, and undergoes oxidative deamination, O-dealkylation followed by 
oxidation, and aliphatic hydroxylation. The metabolites are excreted in the urine with 
only small amounts of unchanged Metoprolol. The rate of metabolism by CYP2D6 is 
determined by genetic polymorphism; the half-life of Metoprolol in fast hydroxylators is 
stated to be 3 to 4 hours, whereas in poor hydroxylators it is about 7 hours. 
Metabolism:  
Metoprolol is metabolized by the cytochrome P450 isoenzyme CYP2D6 and 
therefore exhibits a debrisoquinetype genetic polymorphism.1-3 Poor, intermediate, 
extensive, and ultra rapid metabolisers of metoprolol have been identified, and studies4-6 
have confirmed that plasma-Metoprolol concentrations correlate with metabolize status. 
However, the clinical relevance of these differences is less clear. A retrospective study 
found that the proportion of poor metabolisers among patients who had severe adverse 
effects was higher than expected, but other studies have found no correlation between the 
incidence of adverse effects and metaboliser status. Controlled studies in patients with 
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hypertension and in healthy subjects have found that there is little or no relationship 
between plasma concentrations or metaboliser status and either the incidence of adverse 
effects or the response to therapy. The subject may be further confused by variations in 
the phenotype between ethnic groups. Although the incidence of the poor metaboliser 
phenotype in whites of European origin is reported to be about 9%, a study in 138 
Nigerians failed to identify evidence of polymorphic metabolism, and the authors caution 
against extrapolation of data between different racial groups. 
Uses: 
Metoprolol is a cardio selective beta blocker. It is reported to lack intrinsic 
sympathomimetic activity and to have little or no membrane-stabilizing activity. It is 
used in the management of hypertension, angina pectoris, cardiac arrhythmias, 
myocardial infarction, and heart failure. It is also used in the management of 
hyperthyroidism and in the prophylactic treatment of migraine.  
Over dosage: 
Excessive doses of Metoprolol can cause severe hypotension, bradycardia, 
metabolic acidosis, seizures and cardio respiratory arrest. Blood or plasma concentrations 
may be measured to confirm a diagnosis of poisoning in hospitalized patients or to assist 
in a medico legal death investigation. Plasma levels are usually less than 200 µg/L during 
therapeutic administration, but can range from 1-20 mg/L in overdose victims. 
 
 
 
 
 
 
5.5.2 Hydrochlorothiazide IP74 
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Molecular formula : C7H8ClN3O4S2 
Molecular weight : 297.7 
Molecular structure : 
                                       
                                                                                           
Chemical Name : 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-     
sulphonamide 1,1-dioxide. 
 
Description  :  White to almost white crystalline powder   
Solubility :  A white to almost white coloured crystalline powder.Freely   
soluble in water,  soluble     in methanol, sparingly soluble in 
alcohol and slightly soluble in Isopropyl alcohol 
Melting point   :  274 0C 
Therapeutic category:   
 Antihypertensive Agents 
 Diuretics 
 Sodium Chloride Symporter Inhibitors 
General Description:  
A thiazide diuretic often considered the prototypical member of this class. It 
reduces the reabsorption of electrolytes from the renal tubules. This results in increased 
excretion of water and electrolytes, including sodium, potassium, chloride, and 
magnesium. It has been used in the treatment of several disorders including edema, 
hypertension, diabetes insipidus, and hypoparathyroidism.  
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Mechanism of Action: 
 
Thiazide diuretics act in the distal convoluted tubule, where they block Na–Cl co 
transport.  The Na–Cl cotransport takes place on the luminal surface of distal convoluted 
tubules.Thus, to exert their diuretic action, the thiazides must reach the luminal fluid. 
Since the thiazide diuretics are largely bound to plasma proteins and therefore are not 
readily filtered across the glomeruli, access to the luminal fluid is accomplished by the 
proximal tubule organic acid secretory system. The drugs then travel along the nephron, 
presumably being concentrated as fluid is abstracted ,until they reach their site of 
inhibitory action in the distal convoluted tubule. Especially at higher doses, 
administration of some of the thiazides results in some degree of carbonic anhydrate 
inhibition. However, at usual doses, only chlorothiazide shows any appreciable carbonic 
anhydride inhibitory activity. 
Pharmacokinetics 
 
Hydrochlorothiazide is fairly rapidly absorbed from the gastrointestinal tract. It is 
reported to have a bioavailability of about 65 to 70%. It has been estimated to have a 
plasma half-life of between about 5 and 15 hours and appears to be preferentially bound 
to red blood cells. It is excreted mainly unchanged in the urine. Hydrochlorothiazide 
crosses the placental barrier and is distributed into breast milk. 
Absorption and Elimination: 
 
Orally administered thiazides are rapidly absorbed from the gastrointestinal tract 
and begin to  produce dieresis in about 1 hour. Approximately 50% of an oral dose is 
excreted in the urine within 6 hours. These compounds are organic acids and are actively 
secreted into the proximal tubular fluid by the organic acid secretary mechanism. There 
also appears to be an extra renal pathway for their elimination involving the hepatic–
biliary acid secretary system that is particularly important for thiazide elimination when 
renal function is impaired. The thiazides have a variable effect on elimination of uric 
acid, which also is secreted by the renal acid secretary  mechanism. Administration of 
thiazide diuretics, especially at low doses, may elevate serum uric acid levels and cause 
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gout like symptoms. Following large doses, thiazides may compete with uric acid for 
active reabsorption and thereby may promote uric acid elimination rather than impair it. 
 
Adverse Effects 
 
Thiazides should be used cautiously in the presence of severe renal and hepatic 
disease, since azotemia and coma may result. The most important toxic effect associated 
with this class of diuretics is hypokalemia, which may result in muscular and central 
nervous system symptoms, as well as cardiac sensitization (see Hypokalemia). Periodic 
examination of serum electrolytes for possible imbalances is strongly recommended. 
Appropriate dietary and therapeutic measures for controlling hypokalemia are described 
later in this chapter. The thiazides also possess some diabetogenic potential, and although 
pancreatitis during thiazide therapy has been reported in a few cases, the major 
mechanism contributing to the potential for glucose intolerance is not known. 
 
 
 
 
 
 
 
 
 
 
 
5.6 Excipients profiles: 
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5.6.1 Hydroxypropylmethylcellulose75 
Nonproprietary Names : Hypromellose (BP, JP, PhEur, USP) 
Synonym                        : Benecel, hydroxypropyl methylcellulose, HPMC,  
                                          hypromellosum, Methocel, methylcellulose propylene glycol 
                                          ether, methyl hydroxypropylcellulose, Metolose, pharmacoat. 
Molecular weight           : 10000–1500000. 
Structural Formula 
                                       
Description 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder 
Typical Properties 
pH    : 5.0–8.0 (2% w/w solution)   
Loss on drying  : 45.0% 
Residue on ignition    :  41.5% 
Melting point   :  190–2000C 
 
 
Solubility  
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Soluble in cold water, practically insoluble in hot water, chloroform, ethanol 
(95%), and ether, but soluble in mixtures of ethanol and dichloromethane, mixtures of 
methanol and dichloromethane  and mixtures of water and alcohol.  
Nominal viscosity (mPas): 3 - 100000 (2%w/w solution at 20oC) 
The different commercial grades are available with varying in viscosities, 
Methocel K4M      :  4000 mPas 
Methocel K15M    : 15000 mPas 
Methocel K100M   :  100000 mPas 
Functional Category 
Bioadhesive material, coating agent, controlled-release agent, emulsifying agent, 
extended-release agent, film-forming agent, modified-release agent, solubilizing agent, 
suspending agent, sustained-release agent, tablet binder, thickening agent. 
Applications in Pharmaceutical Formulation or Technology 
Hypromellose is widely used in oral, ophthalmic, nasal, and topical 
pharmaceutical formulations. Concentrations between 2% and 5% w/w may be used as a 
binder in either wet or dry-granulation processes. High-viscosity grades may be used to 
retard the release of drugs from a matrix at levels of 10–80% w/w in tablets and capsules. 
Depending upon the viscosity grade, concentrations of 2–20% w/w are used for film-
forming solutions to film-coat tablets. Hypromellose at concentrations between 0.45–
1.0% w/w may be added as a thickening agent to vehicles for eye drops and artificial tear 
solutions. It is also used commercially in liquid nasal formulations at a concentration of 
0.1%. 
 
 
Incompatibilities 
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It is incompatible with some oxidizing agents. Since it is nonionic, hypromellose 
will not complex with metallic salts or ionic organics to form insoluble precipitates. 
 
5.6.2 Microcrystalline cellulose  
      Non proprietary Name  : Microcrystalline cellulose, 
  Cellulosummicrocrystallinum. 
Empirical formula : (C6H10O5) n Where n = 220 
Molecular weight : 36000 
Applications  :    It is used primarily as a binder/diluent in oral  
                tablet and capsule formulations where it is used  
     in both wet granulation and direct compression  
     processes. It has also got some lubricant, anti- 
     adherent, and disintegrating properties, which  
     make it useful in tabletting. 
Typical Properties 
 Angle of repose : 34.4° 
 Density (bulk)  : 0.337 g/cm3 
 Density (tapped) : 0.478 g/cm3 
 Flow ability  : 1.41 g/s 
 Melting point  : chars at 260 - 270°C. 
      Incompatibilities : Incompatible with strong oxidizing agents. 
                    
 
                          Table : Use of Microcrystalline cellulose 
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Use Concentration (%) 
Adsorbent 20-90 
Anti adherent 5-20 
Capsule binder/diluents 20-90 
Tablet disintegrant 5-15 
Tablet binder/diluents 20-90 
 
5.6.3 Colloidal silicon dioxide  
Nonproprietary Names  : Colloidal anhydrous silica. 
Synonyms    : Aerosil; Cab-O-Sil; Colloidal silica. 
Molecular Weight  : 60.08 
Functional Category   : Adsorbent; anti caking agent; glident;  
      suspending agent; tablet disintegrant;  
      viscosity increasing agent. 
Description    : It is submicroscopic fumed silica with a  
      particle size of about 15 nm it is a light  
      loose bluish white coloured odorless non- 
      gritty amorphous powder  
Bulk density  : 0.029 – 0.042 g/cm³ 
Flow ability               : 35.52% 
Solubility    : Practically insoluble in organic solvents,  
water, and acids except hydrofluoric acid 
soluble in hot solutions of alkali hydroxide. 
Forms a colloidal dispersion with water.  
Incompatibilities   : Incompatible with diethylstilbestrol.  
 
Applications:  
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It is widely used in pharmaceuticals, cosmetics, and food products also used to 
stabilize emulsions and as a thixotropic thickening and suspending agent .In aerosols 
other than those for inhalation colloidal silicon dioxide is used to promote particulate 
suspension, eliminate hard settling and minimize the clogging of spray nozzles also 
used as a tablet disintegrant as an adsorbent dispersing agent for liquids in powders or 
suppositories.  
 
5.6.4 Povidone  
Nonproprietary Names :  Povidone (BP, JP, PhEur, USP) 
   Synonyms                            :                Kollidon, polyvinylpyrollidone, povidonum, PVP. 
1-vinyl-2-pyrollidinone polymer. 
Empirical Formula  :  (C6H9NO)n      
Molecular Weight  :  2500–3000000 
Description                            :  Povidone occurs as a fine, white to creamy-white 
colored, odorless or almost odorless, hygroscopic 
powder.  
Solubility                               :  Freely soluble in acids, chloroform, ethanol 
(95%), ketones, methanol, and water; practically 
insoluble in ether, hydrocarbons, and mineral oil.  
Functional Category         :  Disintegrant; dissolution enhancer, suspending 
agent, tablet binder. 
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Applications in Pharmaceutical Formulation or Technology 
In tableting, povidone solutions are used as binders in wet-granulation processes. 
Povidone is used as a solubilizer in oral and parenteral formulations, and has been shown 
to enhance dissolution of poorly soluble drugs from solid-dosage forms. Povidone 
solutions may also be used as coating agents or as binders. Povidone is additionally used 
as a suspending, stabilizing, or viscosity-increasing agent in a number of topical and 
oralsuspensions and solutions. The solubility of a number of poorly soluble active drugs 
may be increased by mixing with povidone. 
Incompatibilities     :      It forms molecular adducts in solution with 
sulfathiazole,sodiumsalicylate, salicylic acid, 
phenobarbital, tannin, and other compounds. 
5.6.5 Magnesium stearate 
Description   : It is a fine, white, precipitated or milled,  
impalpable powder of low bulk density, having a   
faint odor of stearic acid and a characteristic taste. 
The powder is greasy to touch and readily adheres 
to the skin. 
Molecular weight  : 591.34 
Structural Formula  : [CH3 (CH2) 16 COO] 2 Mg   
Crystalline Forms : High purity magnesium stearate has been  
isolated as a trihydrate, a dihydrate, and an 
anhydrate. 
Flow ability   : Poorly flowing, cohesive powder. 
Melting range : 117-150 oC (commercial samples) 126-130 o C  
(high purity magnesium stearate) 
Solubility : Practically insoluble in ethanol, 
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ether and water; slightly soluble in warm benzene 
and warm ethanol (95 %) 
Functional category  : Tablet and capsule, lubricant. 
Applications   : It is primarily used as a lubricant in capsule and  
tablet manufacture at concentrations between 0.25% 
and 5.0 % w/w. 
Incompatibilities  : Incompatible with strong acids, alkalis, and iron  
salts. Strong oxidizing materials. Magnesium 
stearate cannot be used in products containing 
aspirin, some vitamins and most alkaloidal salts. 
Safety    : Oral consumption of large quantities may result  
in some laxative effect or mucosal irritation. 
 
5.6.6 LACTOSE  
Nonproprietary names   : Lactose (BP), Lactose Monohydrate (PhEUR, USP-NF). 
Synonym                       :      CapsuLac, GranuLac, Lactochem, lactosum monohydricum,                                          
monohydrate, Pharmatose, PrismaLac, SacheLac,  
SorboLac,    pheroLac, SuperTab 30GR,  Tablettose.            
Chemical Name            :  O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose              
monohydrate,  
 Emprical Formula       :   C12H22O11·H2O.   
 Molecular weight        :  360.31 
Description: 
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In solid state, lactose appears as various isomeric forms, depending on the 
crystallization and drying conditions, i.e. αlactose monohydrate, β-lactose anhydrous and 
α-lactose anhydrous. Lactose occurs as white to off-white crystalline particles or powder, 
it is odorless and slightly sweet-tasting. 
Structural formula:  
                         
pH        :   5.5-8.9.(1%w/w aqueous solution at 25o) 
Solubility     :   Insoluble in chloroform, ethanol, ether. Soluble in water in  
.                      Ratio of 1 in 5.24. 
Melting point      :   201–2020C (for dehydrated a-lactose monohydrate) 
 
Moisture content   :  Lactose monohydrate contains normally  
                                   Has a range of 4.5–5.5% w/w water content. 
Functional Category: 
 Dry powder inhaler carrier, lyophilization aid, tablet binder, tablet and capsule 
diluent, tablet and capsule filler. 
Applications in Pharmaceutical formulation or technology: 
Lactose is widely used as a filler and diluent in tablets and capsules. Lactose is 
also used as a diluent in dry-powder inhalation. Lactose is added to freeze-dried solutions 
to increase plug size and aid cohesion. Lactose is also used in combination with sucrose 
to prepare sugar-coating solutions. It may also be used in intravenous injections. Lactose 
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is also used in the manufacture of dry powder formulations for use as aqueous film-
coating solutions or suspensions. Direct-compression grades of lactose monohydrate are 
available as spray-dried lactose and anhydrous lactose. 
Incompatibilities: 
A Maillard-type condensation reaction is likely to occur between lactose and 
compounds with a primary amine group to form brown, or yellow-brown-colored 
products. Lactose is also incompatible with amino acids, amfetamines and lisinopril. 
Stability and storage conditions: 
Mold growth may occur under humid conditions (80% relative humidity and 
above). Lactose may develop a brown coloration on storage, the reaction being 
accelerated by warm, damp conditions. Solutions show autorotation. Lactose should be 
stored in a well-closed container in a cool, dry place. 
Safety: 
Lactose is widely used as a filler and filler-binder in orals and injections. Adverse 
reactions to lactose are largely attributed to lactose intolerance, results in lactose being 
undigested and may lead to cramps, diarrhea, distension, and flatulence.  
 
5.6.7 STARCH:  
Nonproprietary Names 
Maize starch, Potato starch, Rice Starch, Tapioca Starch, Wheat Starch (BP, JP, 
PhEur, USP) 
Synonyms 
Amido, amidon, amilo, amylum, C*PharmGel, Eurylon, fecule, Hylon, maydis 
amylum, Melojel, Meritena, oryzae amylum, Pearl, Perfectamyl, pisi amylum, Pure-Dent, 
Purity 21, Purity 826, solani amylum, tritici amylum, Uni-Pure. 
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Empirical Formula  :  (C6H10O5)n where n = 300–1000. 
Molecular Weight  :  50 - 500 million Da 
Structural Formula 
 
Description 
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It 
consists of very small spherical or ovoid granules or grains whose size and shape are 
characteristic for each botanical variety. 
Typical Properties 
pH   :  4.0–8.0 
 
Moisture content 
All starches are hygroscopic and absorb atmospheric moisture to reach the 
equilibrium humidity. The approximate equilibrium moisture is 12 – 18 % 
Solubility  
Practically insoluble in cold ethanol (96%) and in cold water. Starch becomes 
soluble in hot water at temperatures above the gelatinization temperature. Starches are 
partially soluble in dimethylsulfoxide and dimethylformamide. 
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Functional Category 
Tablet and capsule diluent; tablet and capsule disintegrate; tablet binder; 
thickening agent. 
Applications in Pharmaceutical Formulation or Technology 
Starch act as an antiadherent and lubricant in tableting and capsule filling (3–10% 
w/w).In tablet formulations, freshly prepared starch paste is used at a concentration of 3–
20% w/w (usually 5–10%, depending on the starch type) as a binder for wet granulation. 
Starch is one of the most commonly used tablet disintegrants at concentrations of 3–25% 
w/w;a typical concentration is 15%.Starch, particularly the fine powders of rice and 
wheat starch, is also used in topical preparations for its absorbency of liquids.Starch paste 
is used in ointment formulations, usually in the presence of higher ratios of 
glycerin.Starch has been investigated as an excipient in novel drug delivery systems for 
nasal, and other site-specific delivery systems (colon). They can improve the 
bioavailability of poorly soluble drugs.Starch has also been used in the treatment of 
children’s diarrheal diseases.Starches with a high amylopectin content (waxy starches) 
are used as the starting material for the synthesis of hydroxyethyl starch, a plasma 
volume expander. 
Stability and Storage Conditions 
Dry starch is stable if protected from high humidity.Starch should be stored in an 
airtight container in a cool, dry place 
.Incompatibilities 
Starch is incompatible with strongly oxidizing substances. Colored inclusion 
compounds are formed with iodine. 
Safety: 
It is regarded as an essentially nontoxic and nonirritant material. Both amylose 
and amylopectin have been evaluated as safe and without limitation for daily intake. 
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5.6.8 ISOPROPYL ALCOHOL  
Nonproprietary Names 
Isopropyl Alcohol (BP, JP, PhEur, USP) 
Synonyms 
Alcohol isopropylicus, dimethyl carbinol, IPA, isopropanol, petrohol, 2-propanol, 
sec-propyl  
Chemical Name :  Propan-2-ol            
Empirical Formula :  C3H8O   
Molecular Weight : 60.1 
Structural Formula 
 
Description 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a 
characteristic, spirituous odor and it has a slightly bitter taste. 
Typical Properties 
Boiling point              :  82.40C 
Flammability           :  Flammable. 
Viscosity (dynamic)  : 2.43 mPas at 200C 
            Specific gravity         :  0.786 
 
Solubility  
Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. 
Soluble in acetone; insoluble in salt solutions.  
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Functional Category: Disinfectant, solvent. 
Applications in Pharmaceutical Formulation or Technology 
Isopropyl alcohol is also used as a solvent both for tablet film-coating and for 
tablet granulation, where the isopropyl alcohol is subsequently removed by evaporation. 
It has also been shown to significantly increase the skin permeability of nimesulide. 
Isopropyl alcohol has some antimicrobial activity and a 70% v/v aqueous solution is used 
as a topical disinfectant. Therapeutically, isopropyl alcohol has been investigated for the 
treatment of postoperative nausea or vomiting. 
Storage Conditions 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
Incompatibilities 
 Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid,  
which cause decomposition.  
Safety: 
Isopropyl alcohol is most frequently used in topical pharmaceutical formulations 
where it may act as a local irritant. When applied to the eye it can cause corneal burns 
and eye damage. 
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6. Experimental work 
6.1 Preformulation studies 
6.1.1 Raw material analysis of Metoprolol Succinate USP70: 
Raw material analysis of Metoprolol Succinate was done as per USP by the 
identification test carried out by the Fourier Transform Infra red spectrophotometer 
(FTIR) and the report was shown in fig: 1 
6.1.2 Raw material analysis of Hydrochlorothiazide IP72: 
Raw material analysis of Hydrochlorothiazide was done as per IP by the 
identification test carried out by the Fourier Transform Infra red spectrophotometer 
(FTIR) and the reports were shown in fig: 2 
6.1.3 Drug-Excipients compatibility studies: 
In the tablet dosage form the drug is in intimate contact with one or more 
excipients; the latter could affect the stability of the drug.  Knowledge of drug- 
excipient interactions is therefore very useful to the formulator in selecting 
appropriate excipients. This information may be present for known drugs. For new 
drugs or new excipients, the preformulation scientist must generate the needed 
information. 
6.1.4 Physical observation: 
 Active ingredients were mixed well with all excipients in binary ratio and 
small portion of this mixed powder was placed in cleaned and dried vial in stability 
chamber at 40oC ± 2oC / 75 ± 5% RH and 25oC ± 2oC /60± 5% RH.  Physical 
observation has been carried out visually for 14days and 28days. 
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6.2 Manufacturing process of Bilayer tablets: 
Based on the inferences from excipient compatibility studies, the compatible 
excipient were used for formulation and development using suitable processes. 
Development trials of about 5000 tablets were made and evaluated the physical 
parameters of the blend and the compressed tablets. Such development trial taken 
until tentative formula. 
 6.2.1 Manufacturing process of Metoprolol Succinate sustained release 
granules: 
          Weighed quantity of Metoprolol Succinate, Microcrystalline cellulose PH102, 
Hydroxy propyl methyl cellulose K100M and Hydroxy propyl methyl cellulose K4M 
were sifted through #30 mesh sieve and mixed for 10 minutes in rapid mixer 
granulator. The binder solution containing poly vinyl pyrollidone K30 in Isopropyl 
alcohol was added slowly to the above ingredients and mixed at slow speed, after 
complete addition of binder solution mix well to get the granules. The wet granules 
were loaded in a fluidized bed drier and dried till the moisture content of granules are 
between 2.0 to 3.0.  The dried granules were sifted through #20 mesh sieve, Hydroxy 
propyl methyl cellulose K100, Hydroxy propyl methyl cellulose K4M, Colloidal 
silicon dioxide and purified talc  were loaded in planetary mixer along with the dried 
granules and mixed well for 3 minutes at slow speed.  
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Flow chart of Metoprolol Succinate Granules preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metoprolol 
Succinate 
HPMC 
K100M 
HPMC K4M 
MCC+Ph 102 
30# Mesh 
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HPMC K100, 
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Flow Chart of Hydrochlorothiazide Granules preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Mixing 
     HCTZ 
Lactose DCL11 
MCC PH 102 
Starch 
    30# Mesh 
    Hexagonal 
      Blender 
Magnesium Sterate 
          
   Brilliant Blue 
   30# Mesh    100# Mesh 
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6.2.2 Manufacturing process of Hydrochlorothiazide Immediate Release 
granules: 
Weighed quantity of Hydrochlorothiazide, Microcrystalline cellulose PH102, 
Lactose DCL 11 and Maize starch were sifted through #30 mesh sieve and mixed for 
10 minutes in Hexagonal blender. Colloidal silicon dioxide and magnesium Sterate 
sift through #30 mesh and Brilliant blue lake sift through #100 mesh were loaded in 
blender along with the above sifted material and mixed well for 2 minutes at slow 
speed.  
6.2.3 Compression of Bilayer tablets: 
The quantity of granules for the immediate-release layer was compressed 
lightly using 27 stationary double rotary compression machine (Cad mach, India) 
using 14/32 inch circular shaped plain punches. Over this compressed layer, required 
quantity of the sustained release layer was placed and compressed to obtain hardness 
in the range of 8-12 kg/cm² to form a bilayer tablet of sustained release of Metoprolol 
succinate and immediate release of Hydrochlorothiazide. Then the compressed 
bilayer tablets were evaluated.  
 
6.2.4 Packing of Bilayer tablets (Blister packing): 
         The compressed bilayer tablets were blister packed using Aluminum foil 
(0.025mm thickness) and PVC foil (0.25mm thickness) with blister packing machine 
(PGI pack 240CH). This blister was evaluated for leakage by dipping two blister in 
water and apply vacuum for 2 minutes, then check it.    
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Flow Chart of Bilayer Tablets Of Metoprolol Succinate and 
Hydrochlorothiazide Preparation 
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6.5 Evaluation 
6.5.1 Evaluation of granules: 76 
Bulk density: 
Bulk density is the ratio of the weight of the powder to the bulk volume it 
occupies. it is expressed in gm/ml. Weighed quantity of granules was transferred into 
a 50 ml measuring cylinder without tapping, during transfer the volume occupied by 
granules was measured. Bulk density was measured by using formula. 
                                                          P
 
= m/Vo   
   Where, 
             Pi = Bulk density 
             m = Mass of the blend,  
  Vo = Untapped Volume 
 
 
Tapped Density: 
Weighed quantity of granules was taken into graduated cylinder, volume 
occupied by granules was noted down. Then cylinder was subjected to 500 taps in 
tapped density tester (Electro Lab USP II), the % Volume variation was calculated by 
following formula. 
                                          Pt = m/Vi 
Where,
 
            Pt = Tapped density 
            M = Mass of the blend,  
 Vi = Tapped volume 
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Carr’s compressibility index: 
Compressibility is the ability of powder to decrease in volume under pressure. 
Using untapped density and tapped density the percentage compressibility of granules 
were determined, which is given as Carr’s compressibility index. 
                                           CI=Vi-V0 / Vi × 100 
Where,  
CI     = Compressibility index             
Vo   = Bulk density  
  Vi   = Tapped density                                  
                                Table: Compressibility index                                     
                   
                                         
                                  
  
 
 
 
 
 
Hausner Ratio 
It is measurement of frictional resistance of the drug. It was determined by the 
ratio of tapped density and bulk density.  
                                        Hausner Ratio = Vo/Vi 
Where,  
           Vo = Bulk density  
  Vi  = Tapped density    
     Compressibility index (%) Flow characters 
          <   10            Excellent 
          11-15            Good 
          16-20            Fair 
          21-25            Passable 
          26-31            Poor 
          > 32            Very poor 
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                                        Table:   Hausner ratio 
              
 
 
 
 
 
 
 
 
 
Angle of repose: 
Angle of Repose (θ) is the maximum angle between the surface of a pile of 
powder and horizontal plane. It is usually determined by fixed funnel method and is 
the measure the flow ability of powder/granules. 
Procedure: 
Weighed quantity of granules was passed through a funnel kept at a height of 
2 cm for the base. The powder is passed till it forms heap and touches the tip of the 
funnel. The radius was measured and angle of repose was calculated by using the 
formula. 
                                        θ = tan -1(h/r)                      
 Where,     
           θ = Angle of repose 
           h = height of the heap of pile,  
 r = radius of base of pile    
                  
Flow characters Hausner ratio 
Excellent 1.11 
Good 1.12 – 1.18 
Fair 1.19 – 1.25 
Passable 1.26 – 1.34 
Poor 1.35 – 1.45 
Very poor 1.46 – 1.59 
Very Very poor >1.60 
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    Table:  Flow Properties and Corresponding Angle of Repose 
                                     
 
 
 
 
 
 
 
 
  
Moisture content: 
Initially 5 g of weighed granules were taken and kept for drying at 1050 C for 
a required time in a oven. Then removed and again reweighed and noted as final 
weight. The difference in weight was noted as moisture content. 
        Moisture content      =    initial weight – final weight     ×   100 
                                                           Initial weight              
Evaluation of Metoprolol granules: 
Metoprolol granules were evaluated for its bulk density, tapped density, 
Carr’s index, Hausner ratio, angle of repose and moisture content as per the 
procedure followed for Metoprolol  granules. Their results are tabulated in table 
no.7.6, 7.7. 
 
 
 
 
Flow properties Angle of repose (θ) 
Excellent 25-30 
Good 31-35 
Fair – aid 36-40 
Passable 41-45 
Poor 46-55 
Very poor 56-65 
Very Very poor >66 
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6.5.2 Evaluation of tablets [77]  
6.5.2.1 Evaluation of physical characteristics  
The formulated tablets were evaluated for the following physicochemical 
parameters, 
Thickness: 
          Thickness mainly depends on die filling, physical properties of material to be 
compressed under compression force. There is bound to be a small variation in the 
thickness of individual tablet in a batch. But it should not be apparent to the unaided 
eye. The thickness and diameter were measured by using vernier calipers.  
Hardness: 
Tablet requires certain amount of strength or hardness, measured by 
Monsanto hardness tester. Ten tablets were randomly picked from each formulation 
and evaluated for hardness during manufacturing and is expressed in Kg/cm2. . 
Friability: 
Friability was performed by using Roche friabilator, normally pre weighed ten 
tablets were placed in the plastic chamber of friabilator. This was then operated for 
100 revolutions. Tablets dropping from a distance of six inches with each revolution. 
Tablets are then dusted and reweighed. Loss of less than 1% in weight is considered 
to be acceptable.  
                         Initial wt. – Final wt.                                                
                                 Initial wt.   
 
Weight variation test: 
Twenty tablets were selected randomly and weighed individually. Calculate 
average weight and compare the individual tablet weight to the average. Not more 
than two of the individual weights deviate from the average weight by more than the 
percentage shown in table and none deviate by more than twice the percentage.  
F (%)   
= 
× 100 
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6.5.2.2:  Assay:  
Assay for Metoprolol Succinate and Hydrochlorothiazide 50: 
Chromatographic system: 
Apparatus   : HPLC, PDA detector 
Column   : Inertsil ODS C18,250× 4.6 mm, 5µ 
Flow rate   : 1.0 ml/min 
Wave length   : 222 nm 
Injection volume  : 20µl 
Column temperature  : Ambient 
Diluent: 
1st diluents –Methanol and 2nd diluents – Mobile phase. 
Mobile phase : 
Mix 85 parts of Buffer and 15 parts of Acetonitrile  
Preparation of standard solution: 
Accurately weighed 23.5mg of Metoprolol succinate and 12.4mg 
Hydrochlorothiazide was taken in 100ml volumetric flask and to this 50ml of 
methanol was added and sonicated to dissolve and volume was made up with 
methanol. From this 5ml of above solution was pipetted out in to 50 ml volumetric 
flask and volume was made up with mobile phase.    
Preparation of sample solution: 
        One tablet equivalent to 52.5mg of Metoprolol succinate was taken in 100ml 
volumetric flask and 70ml of methanol was added and sonicated for 30min and 
volume was made up with methanol. From this 10ml of above solution was pipetted 
out in to 50ml volumetric flask and volume was made up with mobile phase. 
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System suitability: 
% RSD of five replicate injections peak should not be more than 2.0% 
The theoretical plate for Metoprolol Succinate and Hydrochlorothiazide peaks should 
not less than 1500. The tailing factor Metoprolol Succinate and Hydrochlorothiazide 
peaks should not more than 2.0 
Procedure: 
20 micro liters of filtered portion of the standard solution and sample solution 
was injected in to HPLC system. The chromatogram was recorded and responses 
were measured for the major peaks. The content of Metoprolol succinate and 
Hydrochlorothiazide per tablet was calculated and followed by the expression.  
Calculation: 
For Metoprolol tartrate 
  Spl Area            Std. wt       5       100     50         Purity    Avg wt     684.81* 
=  ------------ X ------------X ------X------ X ------X--------- X---------X-------- X100 
  Std Area             100           50       LC      5          100         LC          652.81** 
 
*- Molecular weight of Metoprolol tart rate 
** - Molecular weight of Metoprolol Succinate 
For Hydrochlorothiazide 
    Spl Area         Std. wt         5       100        50      Purity (as is)    Avg wt 
=  ------------- X ------------X ------X------ X ------X--------------- X--------X 100 
  Std Area             100           50       LC         5          100                LC   
 
In vitro Dissolution studies: 
Dissolution for Metoprolol Succinate30, 70: 
Six tablets of Metoprolol and Hydrochlorothiazide (Bilayer tablets) were 
placed in the apparatus of USP II (paddle). The medium  used was  500 ml of pH 6.8 
phosphate buffer solutions and the dissolution mediums were maintained at the 
temperature of 37.5± 0.50 C the RPM was fixed in 50 RPM. The sample was 
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withdrawn at of 1st, 4th, 8th and 20th hr time interval. The estimation was carried out by 
HPLC method 
Chromatographic system: 
Apparatus       : HPLC, PDA Detector 
Column           : Inertsil ODS C18, 250× 4.6 mm,5µ 
Wave length    : 222 nm 
Injection volume : 20 µl 
Flow rate         : 1.0 ml/min 
Column Temperature : Ambient 
Diluent   : Dissolution medium 
Mobile phase   : Mix 85 parts of Buffer and 15 parts of Acetonitrile  
Standard preparation: 
Accurately weighed 23.5mg of Metoprolol succinate was taken in 50ml of 
volumetric flask and 25ml of diluents were added and sonicated to dissolve and the 
volume was made up with diluents. From this 5ml was pipetted out in to 50ml 
volumetric flask and volume was made with a diluents. Filtered through 0.45 micron 
membrane filter. 
Sample preparation: 
The dissolution parameters were setted and one tablet is placed in each basket 
and care was taken to exclude air bubbles from the surface of the tablets and 
immediately the apparatus was started after 1st hour, 10ml of the sample was 
withdrawn and filter through whatmann filter paper, 10ml of solution was replaced in 
to dissolution medium, the same procedure was repeated at 4th, 8th and 20th hour.   
Procedure: 
20 micro liters of filtered portion of the standard and sample solution was 
injected in to HPLC system. The chromatogram was recorded and responses were 
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measured for major peaks. The % release of Metoprolol succinate was calculated by 
using following expression. 
Calculation for Metoprolol Succinate: 
    Spl Area         Std. wt         5       500        Purity (as is)    684.81* 
=  ------------- X ------------X ------X------ X --------------- X---------X100 
  Std Area             50            50        LC               100          652.81** 
 
 
*- Molecular weight of Metoprolol tartrate 
** - Molecular weight of Metoprolol Succinate 
 
Dissolution for Hydrochlorothiazide: 
Six tablets of Metoprolol and Hydrochlorothiazide (bilayer tablets) were 
placed in the apparatus of USP I (Basket). The medium used was the 900 ml of 0.1N 
Hydrochloric acid solutions and the dissolution mediums maintained at the 
temperature of 37.5± 0.50 C the RPM was fixed in 100 RPM. The sample withdrawal 
time of 1hr (60 min). The estimation was carried out by HPLC method. 
Chromatographic system: 
Apparatus       : HPLC, PDA Detector 
Column           : Inertsil ODS C18, 250× 4.6 mm, 5µ 
Wave length    : 222 nm 
Injection volume : 100 µl 
Flow rate         : 1.0 ml/min 
Column Temperature : Ambient 
Diluents   : Dissolution medium 
Mobile phase   : Mix 85 parts of Buffer and 15 parts of Acetonitrile  
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Standard preparation: 
Accurately weighed 12.4mg of Hydrochlorothiazide was taken in 200ml 
volumetric flask and 50ml of diluents, kept warm at 50˚C in water bath for 20mins to 
dissolve and volume was made up by the diluents. From this 5ml was pipetted out in 
to 100ml volumetric flask and volume was made up with dissolution medium. 
Sample preparation 
The dissolution parameters were setted and one tablet was placed in to each 
basket care was taken to exclude air bubbles from the surface of the tablets and 
immediately the apparatus was started, after 60th min the sample was withdrawn by 
using whatmann filter. 
Procedure 
100 micro liters of filtered portion of the standard and sample solution was 
injected in to HPLC system. The chromatogram was recorded and the responses were 
measured for the major peaks. The % release of Hydrochlorothiazide was calculated 
an calculated and followed by the expression.   
Calculation for Hydrochlorothiazide: 
    Spl Area         Std. wt         5       900        Purity (as is)     
=  ------------- X ------------X ------X------ X ------------ X100 
     Std Area             200         50       LC           100         
 
 
6.6 Kinetics of drug release 77 
Kinetics of drug release is studied by plotting the data obtained from in vitro 
release in various kinetic models. 
 Zero order equation 
The graph was plotted as % drug released Vs time in hours. 
                               C=K0t 
Where,  
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K0 – Zero order constant in concentration/time 
 t – Time in hours 
The graph would yield a straight line with a slope equal to K0 and intercept 
the origin of the axis. The results were tabulated and graph was shown. 
First order equation 
         The graph was plotted as log % cumulative drug remaining Vs Time in hours. 
  Log C = log C0- Kt /2.303 
Where,  
C0 - Initial concentration of drug.  
 K- First order constant. 
 t- Time in hours 
 
 Higuchi kinetics 
The graph was plotted as % Cumulative drug released Vs square root of time 
    Q = Kt ½ 
Where, 
 K – Constant reflecting design variable system.  
t - Time in hours 
  Hence drug release rate is proportional to the reciprocal of square root of time. 
If the plot yields a straight line, and the slope is one, then the particular dosage form 
is considered to follow Higuchi kinetics of drug release. The results were tabulated. 
 
Korsmeyer – Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in peppas 
equation as log cumulative % of drug released Vs time 
 Mt / Mα = Kt n 
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 Log Mt / M α = log K + n log t 
Where, 
    Mt / Mα - fraction of drug released at time t 
    t – Release time ` 
  K – Kinetic constant (incorporating structural and geometric characteristics of  
preparation) 
    n - Diffusion exponent indicative of the mechanism drug release. 
  If n value is 0.5 or less, the release mechanism follows “ Fickian diffusion” 
and higher values of 0.5 < n< 1 for mass transfer follow a non- fickian model 
(anomalous transport). The drug release follows zero-order drug release and case – II 
transport if the value is 1. For the values of n higher than 1, the mechanism of drug 
release is regard as super case II transport. This model is used to analyze the release 
of pharmaceuticaL polymeric dosage forms when the release mechanism is not 
known or more than one type of release phenomenon was involved. The n value 
could be obtained from slope of the plot of log cumulative % of drug released Vs log 
time.  
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6.7 Stability studies: 69, 78 
 Stability of a drug has been defined as the ability of a particular formulation, 
in a specific container, to remain within its physical, chemical, therapeutics and 
toxicological specifications. The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product varies with time under the 
influence of a variety of environmental factors such as temperature, humidity and 
light, and to establish a retest for the drug substance or a shelf life for the drug 
product and recommended storage conditions. The selected batches  were charged on 
accelerated stability as per ICH guidelines.                                
                                       Table: Storage condition 
S.NO. STUDY STORAGE CONDITION 
1 Long term 25°C±2°C/60%RH±5%RH 
2 Accelerated 40°C±2°C/75%RH±5%RH 
 
Stability studies of selected formulations: 
Stability studies were conducted for the formulation F-8 and F-9 .The storage 
conditions used for stability studies were accelerated condition 
(40°C±2°C/75%±5%RH) and ambient temperature (30°C±2°C/65%±5%RH). Sample 
of tablets were analyzed after 1 month and 2 months for physical characters and assay 
were performed followed by in vitro dissolution test.  
Test Performed: 
1. Test for physical parameters (description, weight variation, friability). 
 2. Assay 
3. In vitro Dissolution Study 
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6.8 FT-IR Studies: 30, 70, 72 
Physical compatibility studies were assured by FT-IR studies. The IR 
spectrums of the mixed powders were taken by preparing Potassium bromide pellets 
under dry condition by using pellet press. Superimposed these spectra. The 
transmission minima (absorption maxima) in the spectra obtained with the sample 
corresponded in position and relative size to those in the spectrum obtained with the 
working/reference standards. 
6.9 Differential Scanning Calorimeter (DSC): 28, 35 
DSC studies also performed to investigate the physical state of the drug in the tablets 
and to know the interactions of drug with polymers in the formulation. Thermal 
properties of pure drug and the formulation were evaluated by (DSC) using Q2000 
24.4 build 116.  
The tablet was ground to powder and a 1-2 mg sample was hermetically sealed in 
an aluminum pan and heated at a constant  rate of 10ºC/min from 30ºC to 300ºC 
temperature range. Inert atmosphere was maintained by purging nitrogen gas at a 
flow rate of 20 ml/min. 
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Table: 7.1 Drug – Excipient compatibility study  
Physical Observation 
 
Sl. 
No 
 
Drug+Excipient 
 
Parameter 
Initial 
Value of 
Parameter 
Condition  
Comments RT40°C±2°C/75% 
±5%RH 
RT25°C±2°C/60% 
±5%RH 
14 days 28 days 14 days 28 days 
1 Metoprolol Succinate Any colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
Compatible 
2 Hydrochlorothiazide Any colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
Compatible 
3 Metoprolol succinate + 
Hydrochlorothiazide 
Any colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
Compatible 
4 Metoprolol succinate + 
Hydrochlorothiazide + 
excipients 
Any colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
Compatible 
5 Placebo Any colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
No colour 
change 
Compatible 
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Table: 7.2 Evaluation of Bilayer tablets of Metoprolol succinate SR and Hydrochlorothiazide IR (F-1 to F-5) 
Sl. 
No 
                Tests       Specifications          F - 1      F - 2      F - 3        F - 4       F - 5 
  1.             Description Blue / White colored 
circular shaped 
uncoated Bilayer 
tablet 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
    2. 
    3. 
    4. 
    5. 
    6. 
 
    7. 
 
Average weight (mg) 
Thickness* (mm) 
Hardness* (kg/cm2) 
Friability *(% w/w) 
Weight variation (n=20) 
   
Assay 
a) Metoprolol succinate 
equivalent to 
Metoprolol tartarate 
b) Hydrochlorothiazide 
       375 mg±3% 
       4.80±0.2 
       NLT 3.0 
       NMT 1%                   
±5% from the average                         
weight 
 
 90 – 110% 
     
                                                                  
90 – 110% 
     376.2 mg 
     4.82±0.2 
     6.5±0.02 
    0.02±0.01 
                                    
+2.1 to -2.3 
 
    95.2% 
 
    96.2% 
 
   376.2 mg 
   4.82±0.2 
   6.5±0.02 
   0.02±0.01 
 
 +2.1 to -2.3 
 
   95.7% 
 
 
    96% 
   377.2 mg 
   4.78±0.2 
   6.5±0.3 
   0.21±0.01 
 
   +2.8 to -2.7 
 
    96.4% 
 
 
    97.1% 
   377.2 mg 
   4.78±0.2 
   7.0±0.02 
   0.19±0.01 
 
   +3.7 to -2.9 
 
    96.2% 
 
 
    98.2% 
 
  376.8 mg 
  4.80±0.2 
  6.5±0.02 
  0.21±0.01 
 
  +2.1 to -2.3 
 
   96.4% 
 
 
   97.1% 
* All the values are mean ±SD, n=6. 
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Table: 7.3 Evaluation of Bilayer tablets of Metoprolol succinate SR and Hydrochlorothiazide IR (F-6 to F-9) 
Sl. No Tests Specifications F - 6 F - 7 F - 8 F - 9 
1. Description Blue / White colored 
circular shaped 
uncoated Bilayer 
tablet 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
Complies 
with internal 
Specifications 
2. 
3. 
4. 
5. 
6. 
 
7. 
 
Average weight (mg) 
Thickness *(mm) 
Hardness* (kg/cm²) 
Friability* (% w/w) 
Weight variation (n=20) 
 
Assay 
a) Metoprolol succinate 
equivalent to 
Metoprolol tartarate 
b) Hydrochlorothiazide 
375±3% 
4.80±0.2 
NLT 3.0 
NMT 1%             
±5% from the average                         
weight 
 
90 – 110% 
 
90 – 110% 
377.4mg 
4.78±0.2 
6.9±0.02 
0.34±0.01 
+3.2 to -2.8 
 
96.6% 
 
 
97.6% 
 
376.2 mg 
4.78±0.2 
7.0 
0.22±0.01 
 
+3.1 to -2.1 
 
96.2% 
 
 
97.1% 
375.2 mg 
4.78±0.2 
7.0 
0.19±0.01 
 
+3.5 to -2.9 
 
99.4% 
 
 
99.7% 
 
375.2 mg 
4.80±0.2 
6.8 
0.19±0.01 
 
+3.1 to -2.1 
 
99.4% 
 
 
99.7% 
* All the values are mean ±SD, n=6. 
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7.4 Dissolution studies 
 In vitro dissolution profile of Bilayer tablet F-1  
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 11.57 46.28±0.03 
2. 4 20 – 40 -- -- 
3. 8 40 – 60 -- -- 
4. 20 NLT 80% -- -- 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) 
 
Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% -- -- 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate sustained 
release and Hydrochlorothiazide immediate release tablet for the formulation F-1. The 
drug release of Metoprolol succinate  at 1st hour was found to be 46.28% which is above  
in the limit , so that dissolution was stopped. 
The release of Hydrochlorothiazide was not found as the tablet compressibility is less. 
 In below Fig: 1 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for formulation F-1  
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 In vitro dissolution profile of Bilayer tablet F-2  
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 3.58 14.33±0.04 
2. 4 20 – 40 17.46 69.84±0.05 
3. 8 40 – 60 -- --- 
4. 20 NLT 80% -- --- 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% 10.29 82.33±0.04 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate and 
Hydrochlorothiazide immediate release tablet for the formulation F-2. The drug release of 
metoprolol succinate at 1st, 4th hour was found to be 14.33, 69.84 respectively. The 4th 
hour release is above in the limit. 
The release of Hydrochlorothiazide at the end of 1 hour was found to be 82.33%. 
In the below Fig: 2 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-2 
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Fig: 1   In vitro dissolution profile of formulation F- 1  
 
 
 
 
                     
 
        Fig:  2 In vitro dissolution profile of formulation F2 
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 In vitro dissolution profile of Bilayer tablet F-3 
Sustained release layer of Metoprolol succinate 
Sl. No Time ( hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative %   
drug release* 
1. 1 NMT 25% 3.11 12.45±0.02 
2. 4 20 - 40 8.84 35.35±0.04 
3. 8 40 - 60 17.08 68.34±0.05 
4. 20 NLT 80% -- --- 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
the drug (mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% 10.72 85.72±0.03 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate sustained 
release and Hydrochlorothiazide immediate release tablet for the formulation F-3. The 
drug release of Metoprolol succinate at 8th hour drug release was obtained from above 
limit. 
The release of Hydrochlorothiazide at the end of 1st hour was found to be 85.72%. 
In the below Fig: 3 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-3. 
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 In vitro dissolution profile of Bilayer tablet F-4 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit(%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 3.59 14.35±0.02 
2. 4 20 – 40 8.67 34.7±0.04 
3. 8 40 – 60 18.16 72.65±0.5 
4. 20 NLT 80% -- -- 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release 
1. 1.0 NLT 60% 11.19 89.5±0.6 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate sustained 
release and Hydrochlorothiazide immediate release tablet for the formulation F-4. The 
drug release in this formulation at 1st, 4th hour release was regulated and 8th hour release 
was above the limit. 
The release of Hydrochlorothiazide at the end of the 1st hour was found to be 89.50%. 
In the below Fig: 4 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-4. 
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Fig: 3   In vitro dissolution profile of formulation F- 3 
 
 
 
 
 
   
 
Fig: 4 In vitro dissolution profile of formulation F- 4 
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 In vitro dissolution profile of Bilayer tablet F-5 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 3.81 15.24±0.03 
2. 4 20 – 40 11.66 46.66±0.05 
3. 8 40 – 60 -- -- 
4. 20 NLT 80% -- -- 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% 11.02 95.4±0.7 
      *all the values are mean ±RSD, n=6 
 
In formulation F-1 to F-5 the SR layer consists of HPMC K100M and HPMC 
K4M in the concentration of 20% to 50% and 2% to 5% with respect to the average 
weight and the weight of the tablet was balanced with Micro crystalline cellulose PH101. 
The release of the drug in F-1 to F-5 was not found to be within the internal specification 
limit. Therefore the release of the drug was more than the limit. The drug release at 4th 
hour was crossing the lmit. 
In the formulation F-2, F-3, F-4 and F-5 starch plain was used as a binder in the 
concentration of 4% to 12% and lubricant concentration is 0.4 to 0.8% respectively to 
meet the compression and dissolution profile of Hydrochlorothiazide with the 
specification limit. At the end of 60 min, the release profile of Hydrochlorothiazide in the 
formulation F-2, F-3, F-4 and F-5 was found to 82.33%, 85.72%, 89.50% and 95.4% 
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respectively. Among these four trials F-5 was found to be satisfactory and it was selected 
as an immediate release layer to formulate with the sustained release layer of Metoprolol 
Succinate as a Bilayer tablet. 
In the below Fig: 5 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-5. 
 In vitro dissolution profile of Bilayer tablet F-6  
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 2.34 9.35±0.05 
2. 4 20 – 40 9.61 42.45±0.04 
3. 8 40 – 60 11.70 62.8±0.18 
4. 20 NLT 80% 20.17 92.65±0.6 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% 11.6 95.4±0.6 
      *all the values are mean ±RSD, n=6 
 
In order to retard the release of the drug, the polymer HPMC K100 concentration was 
increased to 51.67% (26.67% intra granulation and 25%extra granulation) and HPMC 
K4M concentration was increased to 3.33% (1.67% intra granulation and 1.67% extra 
granulation)   in formulation F-6. But the release of the drug at 4th and 8th hour was 
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42.45% and 62.8% higher to the desired release pattern.The drug release at and 1st and 
20th hour was controlled the release and 4th and 8th hour was above the limit.   
The release of the Hydrochlorothiazide at the end of the 1st hour was found to be 95.40%. 
In the below Fig: 6 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-6. 
 
 
 
Fig: 5 In vitro dissolution profile of formulation F- 5                            
 
               
                Fig: 6 In vitro dissolution profile of formulation F- 6 
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 In vitro dissolution profile of Bilayer tablet F-7 
Sustained release layer of Metoprolol succinate 
 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
 
1. 1 NMT 25% 4.07 17.34±0.13 
2. 4 20 – 40 7.69 33.06±0.6 
3. 8 40 – 60 12.85 55.35±0.8 
4. 20 NLT  80% 22.72 97.78±0.16 
Immediate release layer of Hydrochlorothiazide 
 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NLT 60% 11.91 95.29±0.5 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate sustained 
release and Hydrochlorothiazide immediate release tablet for the formulation F-7 to 
increase the release of the drug, the concentration of HPMC K100M was increased to 
1.5% was found to be satisfactory where the drug release of Metoprolol succinate at 1st, 
4th, 8th and 20th hour was found to be, 17.34, 33.06, 55.35, and 97.78% respectively. 
The release of Hydrochlorothiazide at the end of 1 hour was found to be 95.29%. 
In the below Fig: 7 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-7. 
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In vitro dissolution profile of Bilayer tablet F-8 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 4.32 17.29±0.13 
2. 4 20 – 40 8.40 33.62±0.6 
3. 8 40 – 60 12.68 54.71±0.8 
4. 20 NLT 80% 22.48 97.92±0.16 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% 11.90 95.28±0.3 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate sustained 
release and Hydrochlorothiazide immediate release tablet for the formulation F-8. The 
drug release at 1st, 4th, 8th and 20th hour was found to be 17.29, 33.62, 54.71 and 97.92% 
respectively. 
The drug release of the Hydrochlorothiazide at 1st hour was found to be 95.28%. 
 In the below Fig: 8  shows the graph of in vitro drug release profile of sustained release 
of Metoprolol succinate and immediate release of Hydrochlorothiazide for the 
formulation F-8. 
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Fig: 7 In vitro dissolution profile of formulation F- 7 
 
 
 
 
 
Fig: 8 In vitro dissolution profile of formulation F-8 
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 In vitro dissolution profile of Bilayer tablet F-9 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1 NMT 25% 3.33 17.3±0.13 
2. 4 20 – 40 7.39 33.59±0.6 
3. 8 40 – 60 12.7 55.80±0.6 
4. 20 NLT 80% 22.47 97.96±0.8 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release* 
1. 1.0 NLT 60% 11.91 95.2±0.3 
      *all the values are mean ±RSD, n=6 
 
In the above table gives the in vitro dissolution profile of Metoprolol succinate sustained 
release and Hydrochlorothiazide immediate release tablet for the formulation F-9. The 
drug release at 1st, 4th, 8th and 20th hour was found to be 17.3, 33.59, 55.80, and 97.96% 
respectively. 
The release of Hydrochlorothiazide at 1st hour was found to be 95.2%. 
In the below Fig: 9 shows the graph of in vitro drug release profile of sustained release of 
Metoprolol succinate and immediate release of Hydrochlorothiazide for the formulation 
F-9. 
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Fig: 9 In vitro dissolution profile of formulation F-9 
 
          All the batches of Bilayer tablets fulfilled the official requirements of uniformity of 
dosage units. The average percentage deviation of 20 tablets of each formula was less 
than ± 4%.  The thickness and hardness of the tablet ranged from 4.5–4.7mm and 9 - 
10.5kg/cm2 respectively. The percentage friability of all batches ranged from 0.11 to 
0.34%w/w.  The drug content was found to be ranged from 92.65% to 97.8% for 
Metoprolol Succinate and 82.33% to 95.28% for Hydrochlorothiazide.  
 
Formulation development of Bilayer tablet 
        The formulation consists of two layers sustained release layer of Metoprolol 
Succinate and immediate release layer of Hydrochlorothiazide. Development trials of 
about 5000 tablets were taken and evaluated the pre compression and post compression 
parameters of Bilayer tablets. 
Precompressional parameters of Bilayer tablets (bulk density, tapped density, Carr’s 
index, Hausner’s ratio and angle of repose) are in the range of given in official standard, 
indicated that granules prepared by wet granulation method were free flowing. The 
postcompressional parameters of Bilayer tablets (hardness, friability, weight variation, 
thickness and drug content) were within the acceptable limits. The optimized bilayered 
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tablets were selected for FTIR studies and DSC studies did not show any interaction 
between the drug, polymer and excipients.  
 
 
                 
      Fig: 10 Zero order kinetics 
 
        
                 
 
 
 
 
    
                       Fig: 11 first order kinetics 
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Fig: 12 Higuchi diffusion kinetics 
 
 
 
 
 
Fig: 13 Korsmeyer-Peppas equation 
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Table: 7.5 Kinetics studies of Bilayer tablets 
 
                           
Release kinetics 
                                                  
R2 
                               
Zero order 
0.981 
                      
First order 
0.966 
                          
Higuchi 
0.996 
                    
Korsmeyer-
peppas 
0.998 
 
 
Release kinetics study for optimized Bilayer tablet: 
            The kinetics of drug release was determined based on korsmeyer-peppas equation 
obtained by in vitro dissolution data to various kinetics models. 
Accordingly the R2 value was found to 0.981 for zero order, 0.966 for first order, 
0.996 for Higuchi, 0.998 for korsmeyer-peppas plot.  The R2 value of korsemeyer-peppas 
was close to 1 and n value was found to be 1.4.  
Hence the release kinetics was fitted to korsemeyer-peppas equeation follows 
non-fickian diffusion model, and the mechanism of drug release is regarded as super case 
II transport.    
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Evaluation of Metoprolol Succinate Layer –I (SR) and Hydrochlorothiazide Layer-
II (IR) 
Bulk density and tapped density for Metoprolol Succinate sustained release granules were 
found to be between 0.648 to 0.668 and 0.728 to 0.778 respectively. Carr’s index and 
Hausner’s ratio were obtained in the range of 11.82 to 14.51 and 1.13 to 1.17 
respectively. Angle of repose was observed in the range of 25°11΄ to 27°84´. Moisture 
content was found to be between 2.0 to 2.5. The results showed in the Table No: 7.7 
indicate good flow property and compressibility. 
 
Bulk density and Tapped density for Hydrochlorothiazide IR granules were found to be 
between 0.593 to 0.640 and 0.720 to 0.771 respectively. Carr’s index and Hausner ratio 
were obtained in the range of 11.11 to 19.32 and 1.13 to 1.24 respectively. Angle of 
repose was observed between 27°69΄ to 33°70´. The results showed in the Table No: 7.6 
indicate that the granules possessed good flow property and compressibility. 
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7.8 Stability studies: 
 
Table: 7.8.1 In vitro dissolution profile of Bilayer tablet F-8 after stability study at 
40ºCº±2ºC/75%±5%RH after 30 days: 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release 
1. 1 NMT 25% 4.06 17.30±0.04 
 
2. 4 20 – 40 7..64 33.04±0.03 
 
3. 8 40 – 60 12.84 55.68±0.05 
 
4. 20 NLT 80% 22.71 97.76±0.03 
 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative 
%drug release 
1. 1.0 NLT 60% 11.91 95.28±0.01 
 
 
In the above table gives the in vitro dissolution profile of formulation F- 8 after stability 
study at 400C±20C /75%±5% RH after 30 days. The drug release of Metoprolol Succinate 
at 1st, 4th, 8th and 20th h was found to be 17.30%, 33.04%, 55.68% and 97.76% 
respectively.   
The release of Hydrochlorothiazide at the end of 1hr was found to be 95.28 %.  
Fig: 16 show the graph of in vitro drug release profile of formulation F- 8 after stability 
study at 400C±20C /75%±5% RH after 30 days. 
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 Table: 7.8.2   In vitro dissolution profile of Bilayer tablet F- 9 after stability study at 
    400C±20C /75%±5%RH after 30 days 
Sustained release layer of Metoprolol Succinate 
Sl. No Time 
(h) 
Limit 
(%) 
Amount of 
drug release             
(mg) 
Cumulative % drug 
release 
1. 1 NMT 25 4.06 17.32± 0.1 
2. 4 20-40 7.68 33.04± 0.03 
3. 8 40-60 12.83 55.34 ± 0.03 
4. 20 NLT 80 22.71 97.76±0.03 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time 
(h) 
Limit 
(%) 
Amount of 
drug release             
(mg) 
Cumulative % drug 
release 
1. 1 hr NLT 60% 11.89 95.12 ±0.01 
                                                                                                                                                                         
In the above table gives the in vitro dissolution profile of formulation F- 9 after stability 
study at 400C±20C /75%±5% RH after 30 days. The drug release of Metoprolol Succinate 
at 1st, 4th, 8th and 20th h was found to be 17.32%, 33.04%, 55.34% and 97.76% 
respectively.   
The release of Hydrochlorothiazide at the end of 1hr was found to be 95.12 %.  
Fig: 17 show the graph of in vitro drug release profile of formulation F- 9 after stability 
study at 400C±20C /75%±5% RH after 30 days. 
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Table: 7.8.3 In vitro dissolution profile of Bilayer tablet F-8 after stability study at  
40ºCº±2ºC/75%±5%RH after 60 days: 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release 
1. 1 NMT 25% 4.04 17.33±0.04 
2. 4 20 – 40 7.05 32.72±0.03 
3. 8 40 – 60 12.78 55.30±0.04 
4. 20 NLT 80% 22.69 97.64±0.03 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release 
1. 1.0 NLT 60% 11.89 95.19±0.01 
 
 
In the above table gives the in vitro dissolution profile of formulation F- 8 after stability 
study at 400C±20C /75%±5% RH after 60 days. The drug release of Metoprolol Succinate 
at 1st, 4th, 8th and 20th h was found to be 17.33%, 32.72%, 55.30% and 97.64% 
respectively.   
The release of Hydrochlorothiazide at the end of 1hr was found to be 95.19 %.  
Fig: 18 show the graph of in vitro drug release profile of formulation F- 8 after stability 
study at 400C±20C /75%±5% RH after 60 days. 
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Table: 7.8.4  In vitro dissolution profile of Bilayer tablet F-9 after stability study at 
40ºCº±2ºC/75%±5%RH after 60 days: 
Sustained release layer of Metoprolol succinate 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release 
1. 1 NMT 25% 4.05 17.22±0.1 
2. 4 20 – 40 7.59 33.05±0.03 
3. 8 40 – 60 12.75 55.28±0.03 
4. 20 NLT 80% 22.71 97.61±0.03 
Immediate release layer of Hydrochlorothiazide 
Sl. No Time (hr) Limit (%) Amount of 
drug release 
(mg) 
Cumulative % 
drug release 
1. 1.0 NLT 60% 11.70 95.23±0.01 
 
 
In the above table gives the in vitro dissolution profile of formulation F- 9 after stability 
study at 400C±20C /75%±5% RH after 60 days. The drug release of Metoprolol Succinate 
at 1st, 4th, 8th and 20th hr was found to be 17.22%, 33.05%, 55.28% and 97.61% 
respectively.   
The release of Hydrochlorothiazide at the end of 1hr was found to be 95.23 %.  
Fig: 19 show the graph of in vitro drug release profile of formulation F- 9 after stability 
study at 400C±20C /75%±5% RH after 60 days. 
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  Fig:16 In vitro dissolution profile of formulation F- 8  after stability study  at   
400C±20C /75%±5% RH after 30 days 
 
 
 
 
 
 Fig :17  In vitro dissolution profile of formulation F- 9 after stability study  at 
400C±20C /75%±5% RH after 30 days 
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Fig: 18   In vitro dissolution profile of formulation F- 8 after stability study at 
400C±20C /75%±5% RH after 60 days 
 
  
 
 
 
Fig: 19   In vitro dissolution profile of formulation F- 9 after stability study at                               
                                        400C±20C /75%±5% RH after 60 days 
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Reproducibility of batch: 
         To check the reproducibility of batch, another batch (F-8, and F-9) was prepared 
with the same formula of F- 7. The drug release at 1st, 4th, 8th and 20th h was found to be 
17.34%, 33.59%, 55.80% and 97.96% for Metoprolol Succinate and 95.2%for 
Hydrochlorothiazide at 1 hr. Hence, the drug release of reproducibility batch (F-9) was 
observed similar to the optimized batch (F-7). 
 
Stability batch:  
Stability studies were conducted for the formulation F- 8 and F- 9. The stability study 
was performed at 40°C±2°C/75%RH±5%Rh for a specific time period. The tablets were 
analyzed for appearance, weight variation, drug content and in vitro drug release. The 
overall results showed that the formulation is stable at the above mentioned storage 
conditions and were not altered significantly on storage indicating good stability. 
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Table: 7.9 Evalution of Bilayer tablets of Metoprolol succinate sustained release and Hydrochlorothiazide immediate release 
after stability study at 40ºC±2ºC/75%±5%RH 
 
 S.No Tests Specifications               1 Month                2 Month 
  1. Description Blue / White colored 
circular shaped 
uncoated Bilayer 
tablet 
    F – 8 
Complies 
    F – 9 
  Complies 
   F – 8 
  Complies 
   F – 9 
 Complies 
    2. 
    3. 
    4. 
    5. 
    6. 
 
    7. 
 
Average weight (mg) 
Thickness (mm) 
Hardness (kg/cm2) 
Friability (% w/w) 
Weight variation (n=20) 
   
Assay 
a) Metoprolol succinate equivalent 
to Metoprolol tartarate 
b) Hydrochlorothiazide 
       375±3% 
       4.80±0.2 
       NLT 3.0 
       NMT 1%                 
±5% from the average                       
weight 
 
 
   90 – 110% 
    90 – 110% 
375±3% 
4.80±0.24 
6.5±0.02 
0.22±0.01 
±3.8 
 
 
 
   93.6 
    95.6 
375±2% 
4.80±0.24 
6.5±0.02 
0.22±0.01 
±3.8 
 
 
 
     95.2 
      94.4 
375±2% 
4.85±2% 
6.5±4% 
0.28±1% 
±4.1 
 
 
 
    93.2 
     95.1 
 
374±2% 
4.80±4% 
6.5±6% 
0.31±1% 
±3.9 
 
 
 
      95.0 
       94.1 
F-8 and F-9 batches are taken with same bill of materials as F-7. 
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7.10 FT - IR Studies:   
In the figure shows the FT-IR spectra of plain Metoprolol Succinate, plain 
Hydrochlorothiazide, combination of Metoprolol Succinate and Hydrochlorothiazide and 
optimized formulation. 
       IR spectra of pure Metoprolol Succinate  Showed the major bands at 1615cm-1, 
1568 cm-1 for aromatic C=C streching, 2259 cm-1, 2877 cm-1 for  aliphatic C-H stretching, 
1072 cm-1 for C=O stretching. 
         IR spectra of pure Hydrochlorothiazide showed the major bands at 1601cm-1 
,1604 cm-1 C=C for aromatic carbon stretching for So2 1335 cm-1, 1151 cm-1 and  3393 
cm-1 , 3363 cm-1 for N-H  and the C-H stretching in aliphatic  ring at 2851cm-1, 2925 cm-1 
         The results of IR spectra of active ingredients and excipients also revealed that 
there was no considerable change in the peaks was observed in bands of Metoprolol 
Succinate and Hydrochlorothiazide, hence there is no interaction between the drug, 
polymer and excipients used in the tablet. 
 
7.11 DSC Studies: 
DSC curves showed that there was no any incompatibility between Metoprolol succinate  
and Hydrochlorothiazide. In the combination DSC, one peak was obtained at 141.60°C 
for Metoprolol succinate and another at 272.50 °C for Hydrochlorothiazide. In the 
individual DSC studies of the drugs, Metoprolol succinate peak was obtained at 138.65 
°C and Hydrchlorothiazide  peak at 29.53°C. These peaks match the peaks reported in the 
literature for pure drugs. 
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                                            Conclusion 
The present research was carried out to develop a bilayer tablet of Metoprolol 
Succinate using hydrophilic matrix formers such as HPMC K100M and HPMC K4M for 
the sustained release layer. Starch is used as a binder for immediate release layer of 
Hydrochlorothiazide. 
 Combination of Metoprolol Succinate and Hydrochlorothiazide are indicated for 
the treatment and relief of Antihypertensive agent  
  Tablet formulation (F-7) showed acceptable pharmacotechnical properties and 
complied with the internal specification for weight variation, thickness, hardness, 
friability, drug content and in vitro drug release. Drug release from the matrix was found 
to decrease with increase in polymer concentration in intra and extra granulation, where 
the polymer concentration was employed from 20-50%w/w of the average tablet weight. 
However, HPMC 4M required to channelize the drug release was optimized with 2% to 
5%. Similarly starch with 12%w/w optimized from 4% onwards, as binder to compress 
IR layer and dissolution within 60 minutes (internal specification).          
 Reproducibility was checked by intra batch variability study and found no 
pronounced variation was observed. 
  The optimized bilayered tablets followed Korsmeyer-peppas kinetic and showed 
no significant change in physical appearance, drug content or in vitro dissolution pattern 
after storage at 40°C/75%RH for 2 months. Hence, it is finally concluded that, the 
Bilayer tablet technology can be successfully applied for sustained release of Metoprolol 
Succinate and immediate-release of Hydrochlorothiazide. 
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